DISUBSTITUTED PYRAZOLINES AND TRIAZOLINES AS FACTOR XA INHIBITORS

Abstract: The present application describes disubstituted pyrazolines and triazolines of formulae (I) and (II), or pharmaceutically acceptable salt forms thereof, wherein one of M<1> and M<2> may be N and D may be a variety of N-containing groups, which are useful as inhibitors of factor Xa.

Description: TITLE DISUBSTITUTED PYRAZOLINES AND TRIAZOLINES AS FACTOR XA INHIBITORS FIELD OF THE INVENTION This invention relates generally to disubstituted pyrazolines and triazolines which are inhibitors of trypsin- like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders. BACKGROUND OF THE INVENTION WO 95/18111 addresses fibrinogen receptor antagonists, containing basic and acidic termini, of the formula: wherein R 1 represents the basic termini, U is an alkylene or heteroatom linker, V may be a heterocycle, and the right hand portion of the molecule represents the acidic termini. The presently claimed compounds do not contain the acidic termini of WO 95/18111. In U.S. Patent No. 5,463,071, Himmelsbach et al depict cell aggregation inhibitors which are 5-membered heterocycles of the formula : wherein the heterocycle may be aromatic and groups A-B-C- and F-E-D- are attached to the ring system. A-B-C- can be a wide variety of substituents including a basic group attached to an aromatic ring. The F-E-D- group, however, would appear to be an acidic functionality which differs from the present invention. Furthermore, use of these compounds as inhibitors of factor Xa is not discussed. WO 97/47299 describes amidino and guanidino heterocyclic protease inhibitors of the formula: R i -Z-X-Y-W wherein W contains an amidino, guanidino, or imino group attached to a variety of moieties including phenyl and piperidinyl, Y is a 0, N, S, or C linker or is absent, X is a heterocycle, Z is a two atom linker containing at least one heteroatom, and R 1 is a variety of groups including cycloalkyl, aryl, heteroaryl, and araalkyl all of which are optionally substituted. A variety of proteases are described as possible targets for these compounds including Factor Xa. The presently claimed compounds differ in that they do not contain the combination R 1 -Z or Y-W. WO 97/23212 describes isoxazolines , isothiazolines, and pyrazolines of the formula: wherein X is O, S or NR 15 . Though the pyrazolines of WO 97/23212 are indicated to be factor Xa inhibitors, they are not considered part of the present invention. Activated factor Xa, whose major practical role is the generation of thrombin by the limited proteolysis of prothrombin, holds a central position that links the intrinsic and extrinsic activation mechanisms in the final common pathway of blood coagulation. The generation of thrombin, the final serine protease in the pathway to generate a fibrin clot, from its precursor is amplified by formation of prothrombinase complex (factor Xa, factor V, Ca2 + and phospholipid) . Since it is calculated that one molecule of factor Xa can generate 138 molecules of thrombin (Elodi, S., Varadi, K. : Optimization of conditions for the catalytic effect of the factor IXa-factor VIII Complex: Probable role of the complex in the amplification of blood coagulation . Thromb. Res . 1979, 15, 617-629), inhibition of factor Xa may be more efficient than inactivation of thrombin in interrupting the blood coagulation system. Therefore, efficacious and specific inhibitors of factor Xa are needed as potentially valuable therapeutic agents for the treatment of thromboembolic disorders . It is thus desirable to discover new factor Xa inhibitors. SUMMARY OF THE INVENTION Accordingly, one object of the present invention is to provide novel disubstituted pyrazolines and triazolines which are useful as factor Xa inhibitors or pharmaceutically acceptable salts or prodrugs thereof . It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof. It is another object of the present invention to provide a method for treating thromboembolic disorders comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof . These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that compounds of formulae I and II: I II or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, D, E, G, M, Z, R l , R lb , and s are defined below, are effective factor Xa inhibitors. DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS [1] Thus, in a first embodiment, the present invention provides novel compounds of formulae I or II: I II or a stereoisomer or pharmaceutically acceptable salt thereof, wherein; M 1 is N or CR lc ; M 2 is NR la or CR la R la , provided that only one of M 1 and M 2 is a N atom; D is selected from C (=NR 8 ) NR 7 R 9 , NHC (=NR 8 )NR 7 R 9 , NR 8 CH(=NR 7 ), C(0)NR 7 R 8 , and CR 8 R 9 NR 7 R 8 ; E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, and piperidinyl substituted with 1 R; alternatively, D-E-G together represent pyridyl substituted with 1 R; R is selected from H, Cl, F, Br, I, (CH ) t 0R 3 , C 1 - 4 alkyl, OCF 3 , CF 3 , C(0)NR 7 R 8 , and (CR 8 R 9 ) t NR 7 R 8 ; G is selected from NHCH , OCH , and SCH 2 , provided that when s is 0, then G is absent; Z is selected from a C 1 - 4 alkylene, (CH 2 ) r O (CH ) r , (CH 2 ) r NR 3 (CH 2 ) r , (CH 2 ) r C(0) (CH 2 ) r , (CH 2 ) r C (0) O (CH 2 ) r , (CH 2 ) r 0C(0) (CH 2 ) r , (CH 2 ) r C(0)NR 3 (CH 2 ) r , (CH 2 ) r NR 3 C(0) (CH 2 ) r , (CH 2 ) r OC (0) O (CH 2 ) r , (CH 2 ) r OC(0)NR 3 (CH 2 ) r , (CH 2 ) r NR 3 C(0)0(CH 2 ) r , (CH 2 ) r NRC(0)NR 3 (CH 2 ) r , (CH 2 ) r S (0) p (CH 2 ) r , (CH 2 ) r S0 2 NR 3 (CH 2 ) r , (CH 2 ) r NR 3 S0 2 (CH 2 ) r , and (CH 2 ) r NR 3 S0 2 NR 3 (CH ) r , provided that Z does not form a N- N, N-0, N-S, NCH 2 N, NCH 2 0, or NCH 2 S bond with group A; R l and R lb are, at each occurrence, independently selected from H, -(CH2) r -R 1 '/ NCH2R 1 ", OCH2R 1 ", SCH2R 1" , N(CH 2 ) 2 (CH 2 ) t R 1 ', 0(CH 2 ) 2 (CH 2 ) t R 1 ', and S (CH 2 ) 2 (CH 2 ) R 1 ' ; RI C i s selected from H, -(CH 2 ) q -R 1 ', Cι_ 3 alkyl, C(0)R 2c , (CF 2 ) r Cθ 2 R 2c , C(0)NR 2 R 2a , C 3 -. 6 carbocyclic residue substituted with 0-2 R 4 , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4 ; R 1 ' is selected from H, C 1 -. 3 alkyl, halo, (CF ) r CF 3 , OR 2 , NR 2 R 2a , C(0)R 2c , OC(0)R 2 , (CF 2 ) r C0 2 R 2c , S(0) p R 2b , NR 2 (CH 2 ) r OR 2 , NR 2 C(0)R 2b , NR 2 C (0)NHR 2b , NR 2 C(0) 2 R 2a , OC(0)NR 2b , C(0)NR 2 R 2a , S0 2 NR 2 R 2a , NR 2 S0 2 R 2b , C 3 - 6 carbocyclic residue substituted with 0-2 R 4 , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4 ; R 1 " is selected from H, C(0)R 2b , C(0)NR 2 R 2a , S(0)R 2b , S(0) 2 R 2b , and S0 2 NR 2 R 2a ; R 2 , at each occurrence, is selected from H, CF 3 , Cχ- 6 alkyl, benzyl, C 3 - 6 carbocyclic residue substituted with 0-2 R 4b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4b ; R a , at each occurrence, is selected from H, CF 3 , Cχ_ 6 alkyl, benzyl, C 3 _ 6 carbocyclic residue substituted with 0-2 R b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4b ; R 2b , at each occurrence, is selected from CF 3 , C 1 - 4 alkoxy, C 1 - 6 alkyl, benzyl, C 3 -. 6 carbocyclic residue substituted with 0-2 R b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R b ; R 2c , at each occurrence, is selected from CF 3 , OH, Cι_ 4 alkoxy, C 1 - 6 alkyl, benzyl, C 3 -. 6 carbocyclic residue substituted with 0-2 R 4b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R b ; alternatively, R 2 and R 2a combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R 4b which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S; R 3 , at each occurrence, is selected from H, Cχ_ 4 alkyl, and phenyl ; R 3a , at each occurrence, is selected from H, Cι_ 4 alkyl, and phenyl ; A is selected from: C 3 -1 0 carbocyclic residue substituted with 0-2 R 4 , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4 ; B is selected from: X-Y, NR 2 R 2a , C(=NR 2 )NR 2 R 2a , NR 2 C (=NR 2 )NR 2 R 2a , C 3 -1 0 carbocyclic residue substituted with 0-2 R a , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4a ; X is selected from C1-4 alkylene, -CR 2 (CR 2 R 2b ) (CH 2 ) t -, -C(O)-, -C(=NR)-, -CR 2 (NR 1 "R 2 )-, -CR 2 (OR 2 )-, -CR 2 (SR 2 )-, -C(0)CR 2 R 2a -, -CR 2 R 2 C(0), -S(0) p -, -S (O) p CR 2 R 2a - , -CR 2 R 2a S(0) p -, -S(0) 2 NR 2 -, -NR 2 S(0) 2 -, -NR 2 S (0) 2 CR 2 R 2 -, -CR 2 R 2a S(0) 2 NR 2 -, -NR 2 S(0) NR 2 -, -C(0)NR 2 -, -NR 2 C(0)-, -C(0)NR 2 CR 2 R 2a -, -NR 2 C(0)CR 2 R 2a -, -CR 2 R 2a C (O)NR 2 -, -CR 2 R 2 NR 2 C(0)-, -NR 2 C(0)0-, -0C(0)NR 2 -, -NR 2 C (O)NR 2 -, -NR 2 -, -NR 2 CR 2 R 2a -, -CR 2 R 2a NR 2 -, 0, -CR 2 R 2a O- , and -OCR 2 R 2a - ; Y is selected from: (CH 2 ) r NR 2 R 2a , provided that X-Y do not form a N-N, O-N, or S-N bond, C 3 _ιo carbocyclic residue substituted with 0-2 R 4 , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4a ; R 4 , at each occurrence, is selected from =0, (CH 2 ) r OR 2 , halo, C1-4 alkyl, -CN, N0 2 , (CH 2 ) r NR 2 R 2a , (CH 2 ) r C (0)R 2b , NR 2 C(0)R 2b , C(0)NR 2 R 2a , NR 2 C (0)NR 2 R 2a , CH (=NR 2 )NR 2 R 2a , NHC(=NR 2 )NR 2 R 2a , S0 2 NR 2 R 2a , NR 2 S0NR 2 R 2a , NR 2 S0 2 -Cι_ alkyl, NR 2 S0 R 5 , S(0) p R 5 , (CF 2 ) r CF 3 , NCH2R 1 ", OCH2R 1" , SCH2R 1 ", N(CH 2 ) 2 (CH 2 ) t Rl', 0 (CH 2 ) 2 (CH 2 ) t R 1 ' , and S(CH 2 ) 2 (CH 2 ) t R 1 ', alternatively, one R 4 is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S; R 4a , at each occurrence, is selected from =0, (CH ) r OR 2 , halo, Cι- 4 alkyl, -CN, N0 2 , (CH 2 ) r NRR 2a , (CH ) r C (0) R 2b , NR 2 C(0)R 2b , C(0)NR 2 R 2a , NR 2 C (0)NR 2 R 2a , CH (=NR 2 ) NR 2 R 2 , NHC(=NR 2 )NR 2 R 2a , S0 2 NR 2 R 2a , NR 2 S0 2 NR 2 R 2a , NR 2 S0 2 -C 1 _ 4 alkyl, NR 2 S0 2 R 5 , S(0) P R 5 , and (CF 2 ) r CF 3 ; alternatively, one R 4a is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-1 R 5 ; R b , at each occurrence, is selected from =0, (CH ) r OR 3 , halo, Ci- 4 alkyl, -CN, N0 2 , (CH 2 ) r NR 3 R 3a , (CH 2 ) r C (0) R 3 , NR 3 C(0)R 3a , C(0)NR 3 R 3a , NR 3 C (0)NR 3 R 3a , CH(=NR 3 )NR 3 R 3a , NH 3 C(=NR 3 )NR 3 R 3a , S0 2 NR 3 R 3a , NR 3 S0 2 NR 3 R 3a , NR 3 S0 2 -Ci- alkyl, NR 3 S0CF 3 , NR 3 S0 2 -phenyl , S(0) p CF 3/ S(0) p -Cι_ 4 alkyl, S (0) p -phenyl, and (CF 2 ) r CF 3 ; R 5 , at each occurrence, is selected from CF 3 , C -β alkyl, phenyl substituted with 0-2 R 6 , and benzyl substituted with 0-2 R 6 ; R 6 , at each occurrence, is selected from H, OH, (CH ) r 0R 2 , halo, C1-4 alkyl, CN, N0 2 , (CH 2 ) r NR R 2a , (CH 2 ) r C (0)R 2b , NR 2 C(0)R 2b , NR 2 C(0)NR R 2a , CH(=NH)NH 2 , NHC(=NH)NH 2 , S0 NR 2 R a , NR 2 S0 2 NR 2 R 2a , and NR 2 S0 2 Cι_4 alkyl; R 7 , at each occurrence, is selected from H, OH, C 1 - 6 alkyl, Cι_ 6 alkylcarbonyl , C 1 - 6 alkoxy, Cχ_ 4 alkoxycarbonyl , (CH 2 ) n -phenyl, C 6 - 10 aryloxy, Cβ-io aryloxycarbonyl , Cβ-io arylmethylcarbonyl , Cι_ 4 alkylcarbonyloxy C 1 - 4 alkoxycarbonyl, C 6 _ιo arylcarbonyloxy C 1 - 4 alkoxycarbonyl, C 1 - 6 alkylaminocarbonyl , phenylaminocarbonyl , and phenyl C 1 - 4 alkoxycarbonyl; R 8 , at each occurrence, is selected from H, Cι_ 6 alkyl and (CH 2 ) n -phenyl; alternatively, R 7 and R 8 combine to form a 5 or 6 membered saturated, ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S; R 9 , at each occurrence, is selected from H, C__ 6 alkyl and (CH 2 ) n -phenyl; n, at each occurrence, is selected from 0, 1, 2, and 3 ; m, at each occurrence, is selected from 0, 1, and 2; p, at each occurrence, is selected from 0, 1, and 2 ; q, at each occurrence is selected from 1 and 2; r, at each occurrence, is selected from 0, 1, 2, and 3; s, at each occurrence, is selected from 0, 1, and 2; and, t, at each occurrence, is selected from 0 and 1. [2 ] In a preferred embodiment , the present invention provides novel compounds of formulae la-lb : wherein; Z is selected from a CH 2 0, OCH 2 , CH 2 NH, NHCH 2 , C(O), CHC(0), C(0)CH 2 , NHC(O), C(0)NH, CH 2 S(0) 2 , S(0) 2 (CH 2 ), S0 2 NH, and NHS0 , provided that Z does not form a N-N, N-O, NCH 2 N, or NCH 2 0 bond with group A; A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ; phenyl , piperidinyl , piperazinyl , pyridyl , pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl , triazolyl, 1, 2, 3-oxadiazolyl, 1, 2 , 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1,2, 4-thiadiazolyl, 1, 2 , 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2 , 3-triazolyl, 1, 2, 4-triazolyl, 1, 2 , 5-triazolyl, 1, 3 , 4- riazolyl, benzofuranyl , benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl , benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl; B is selected from: Y, X-Y, NR 2 R 2a , C (=NR 2 )NR 2 R 2 , and NR 2 C(=NR 2 )NR 2 R 2a ; X is selected from C 1 -. 4 alkylene, -C(O)-, -C(=NR)-, -CR 2 (NR 2 R 2a )-, -C(0)CR 2 R 2a -, -CR 2 R 2a C(0), -C(0)NR 2 -, -NR 2 C(0)-, -C(0)NR 2 CR 2 R 2a -, -NR 2 C (0) CR 2 R 2a -, -CR 2 R 2a C(0)NR 2 -, -CR 2 R 2a NR 2 C(0)-, -NR 2 C (0) NR 2 - , -NR 2 -, -NR 2 CR 2 R 2 -, -CR 2 R 2a NR 2 -, O, -CR 2 R 2a 0-, and -0CR 2 R 2a -; Y is NR 2 R 2a , provided that X-Y do not form a N-N or 0-N bond; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R a ; cylcopropyl, cyclopentyl, cyclohexyl, phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3-oxadiazolyl, 1, 2, 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1,2, 4-thiadiazolyl, 1,2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2 , 3-triazolyl, 1,2,4-triazolyl, 1, 2 , 5-triazolyl, 1, 3 , 4-triazolyl, benzofuranyl , benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl , benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl; alternatively, Y is selected from the following bicyclic heteroaryl ring systems: K is selected from O, S, NH, and N. [3] In a more preferred embodiment, the present invention provides novel compounds of formulae la-lb, wherein; Z is selected from a C(O), CH 2 C(0), C(0)CH 2 , NHC(O), C(0)NH, C(0)N(CH 3 ), CH 2 S(0) 2 , S(0) 2 (CH 2 ), S0 2 NH, and NHS0 2 , provided that Z does not form a N-N or NCH 2 N bond with group A. [4] In an even more preferred embodiment, the present invention provides novel compounds of formulae la-lb, wherein; E is phenyl substituted with R or 2-pyridyl substituted with R; D is selected from C(0)NH 2 , C(=NH)NH 2 , CH 2 NH 2 , CH 2 NHCH 3 , CH(CH 3 )NH 2 , and C(CH 3 ) 2 NH 2 ; and, R is selected from H, OCH 3 , Cl, and F. [5] In a further preferred embodiment, the present invention provides novel compounds of formulae la-lb, wherein; D-E is selected from 3-amidinophenyl, 3-aminomethylphenyl, 3- aminocarbonylphenyl , 3 - (methylaminomethyl) phenyl, 3- ( 1- aminoethyl) phenyl , 3- (2-amino-2-propyl) phenyl, 4-chloro- 3-amidinophenyl, 4-chloro-3-aminomethylphenyl, 4-chloro- 3- (methylaminomethyl)phenyl, 4-fluoro-3-amidinophenyl, 4- fluoro-3-aminomethylphenyl, 4-fluoro-3- (methylaminomethyl) phenyl, 6-amidinopyrid-2-yl, 6- aminomethylpyrid-2-yl, 6-aminocarbonylpyrid-2-yl, 6- (methylaminomethyl)pyrid-2-yl, 6- (l-aminoethyl)pyrid-2- yl, and 6- (2-amino-2-propyl)pyrid-2-yl. [6] In another even more preferred embodiment, the present invention provides novel compounds of formulae la-lb, wherein; Z is C(0)CH 2 and CONH, provided that Z does not form a N-N bond with group A; A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R 4 ; and, B is selected from X-Y, phenyl, pyrrolidino, morpholino, 1, 2 , 3-triazolyl, and imidazolyl, and is substituted with 0-1 R a ; R 4 , at each occurrence, is selected from OH, (CH 2 ) r OR 2 , halo, Cι_ 4 alkyl, (CH 2 ) r NR 2 R 2a , and (CF 2 ) r CF 3 ; R 4a is selected from Cι_ 4 alkyl, CF 3 , S(0) p R 5 , S0NR 2 R 2a , and l-CF 3 -tetrazol-2-yl; R 5 , at each occurrence, is selected from CF 3 , Cι_ 6 alkyl, phenyl, and benzyl ; X is CH 2 or C(O); and, Y is selected from pyrrolidino and morpholino. [7] In another further preferred embodiment, the present invention provides novel compounds of formulae la-lb, wherein; A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl, 2-aminophenyl, and 2- methoxyphenyl; and, B is selected from the group: 2-CF3-phenyl , 2- (aminosulfonyl)phenyl, 2- (methylaminosulfonyl) phenyl, 2- (dimethylaminosulfonyl) phenyl, 1-pyrrolidinocarbonyl, 2- (methylsulfonyl) phenyl, 4-morpholino, 2- (1 ' -CF3-tetrazol- 2-yl)phenyl, 4-morpholinocarbonyl, 2-methyl-l-imidazolyl, 5-methyl-l-imidazolyl, 2-methylsulfonyl-l-imidazolyl and, 5-methyl-l, 2, 3-triazolyl . [8] In another even more preferred embodiment, the present invention provides novel compounds of formulae la-lb, wherein; E is phenyl substituted with R or 2-pyridyl substituted with R; D is selected from C(0)NH 2 , C(=NH)NH 2 , CH 2 NH 2 , CH 2 NHCH 3 , CH(CH 3 )NH 2 , and C(CH 3 ) 2 NH 2 ; and, R is selected from H, OCH 3 , Cl, and F; Z is C(0)CH and CONH, provided that Z does not form a N-N bond with group A; A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R 4 ; and, B is selected from X-Y, phenyl, pyrrolidino, morpholino, 1, 2, 3-triazolyl, and imidazolyl, and is substituted with 0-1 R a ; R 4 , at each occurrence, is selected from OH, (CH ) r OR 2 , halo, Cι- 4 alkyl, (CH 2 ) r NRR 2a , and (CF 2 ) r CF 3 ; R a is selected from Cι_ alkyl, CF 3 , S(0) p R 5 , S0NR 2 R 2 , and l-CF 3 -tetrazol-2-yl; R 5 , at each occurrence, is selected from CF 3 , Cι-β alkyl, phenyl , and benzyl,- X is CH or C(O); and, Y is selected from pyrrolidino and morpholino , [9] In another further preferred embodiment, the present invention provides novel compounds of formulae la-lb, wherein; D-E is selected from 3-amidinophenyl, 3-aminomethylphenyl, 3- aminocarbonylphenyl , 3 - (methylaminomethyl) phenyl, 3- ( 1- aminoethyl)phenyl, 3- (2-amino-2-propyl) phenyl, 4-chloro- 3-amidinophenyl , 4-chloro-3-aminomethylphenyl, 4-chloro- 3- (methylaminomethyl) henyl, 4-fluoro-3-amidinophenyl, 4- fluoro-3-aminomethylphenyl, 4-fluoro-3- (methylaminomethyl) henyl, 6-amidinopyrid-2-yl, 6- aminomethylpyrid-2-yl, 6-aminocarbonylpyrid-2-yl, 6- (methylaminomethyl)pyrid-2-yl, 6- (l-aminoethyl)pyrid-2- yl, 6- (2-amino-2-propyl)pyrid-2-yl; A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl , 2-aminophenyl, and 2- methoxyphenyl ; and, B is selected from the group: 2-CF3-phenyl , 2- (aminosulfonyl) phenyl, 2- (methylaminosulfonyl) phenyl, 2- (dimethylaminosulfonyl) phenyl, 1-pyrrolidinocarbonyl, 2- (methylsulfonyl) phenyl, 4-morpholino, 2- (1 ' -CF3~tetrazol- 2-yl)phenyl, 4-morpholinocarbonyl, 2-methyl-1-imidazolyl, 5-methyl-l-imidazolyl, 2-methylsulfonyl-l-imidazolyl and, 5-methyl-l,2,3 -triazolyl . [10] In a still further preferred embodiment, the present invention provides a novel compound of formula la. [11] In another still further preferred embodiment, the present invention provides a novel compound of formula lb. [12] In another even more preferred embodiment, the present invention provides novel compounds of formulae la-lb, wherein; D is selected from C ( =NR 8 ) NR 7 R 9 , C(0)NR 7 R 8 , NR 7 R 8 , and CH 2 NR 7 R 8 ; E is phenyl substituted with R or pyridyl substituted with R; R is selected from H, Cl, F, OR 3 , CH 3 CH 2 CH 3 , 0CF 3 , and CF 3 ; Z is selected from C(O), CH 2 C(0), C(0)CH 2 , NHC(O), and C(0)NH, provided that Z does not form a N-N bond with group A; R la and R lb are, at each occurrence, independently selected from H, -(CH 2 )r-R 1 '» NCH2R 1 ", OCH2R 1" , SCH2R 1" , N(CH 2 )2(CH 2 ) t R 1' , 0(CH 2 ) 2 (CH 2 ) t R 1' , and S ( CH 2 ) 2 ( CH 2 ) tR 1' ; R lc is selected from H, -(CH 2 ) q -R 1 ', Cι_ 3 alkyl, C(0)R 2c , (CF 2 ) r C0 2 R 2c , and C(0)NR 2 R 2a ; R 1 ', at each occurrence, is selected from H, Cχ_ 3 alkyl, halo, (CF 2 ) r CF 3 , OR 2 , NR 2 R 2a , C(0)R 2c , (CF 2 ) r C0 2 R 2c , S(0) p R 2b , NR (CH 2 ) r 0R 2 , NR 2 C(0)R 2b , NR 2 C(0) 2 R 2b , C(0)NR 2 R a , S0 2 NR 2 R 2 , and NR 2 S0 2 R 2b ; A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl , pyrazolyl , and imidazolyl ; B is selected from: Y, X-Y, NR 2 R 2a , C (=NR 2 )NR 2 R 2a , and NR 2 C(=NR 2 )NR 2 R 2a ; X is selected from CH 2 , -CR 2 (CR 2 R 2b ) (CH 2 ) t -, -C(O)-, -C(=NR)-, -CH(NR 2 R 2a )-, -C(0)NR 2 -, -NR 2 C(0)-, -NR 2 C (O)NR 2 - , -NR 2 -, and 0; Y is NR 2 R 2a , provided that X-Y do not form a N-N or 0-N bond; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4a ; phenyl , piperidinyl , piperazinyl , pyridyl , pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3-oxadiazolyl, 1,2, 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1,2, 4-thiadiazolyl, 1,2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2, 3-triazolyl, 1,2, 4-triazolyl, 1, 2 , 5-triazolyl, and 1, 3 , 4-triazolyl; R 4 , at each occurrence, is selected from =0, OH, Cl, F, C 1 - 4 alkyl, (CH 2 ) r NR 2 R a , (CH 2 ) r C (0)R 2b , NR 2 C(0)R 2b , C(0)NR 2 R 2a , CH(=NH)NH 2 , NHC(=NH)NH 2 , S0 2 NR 2 R 2a , NR 2 S0 2 -Cι_ 4 alkyl, NR 2 S0 2 R 5 , S(0) p R 5 , and (CF 2 ) r CF 3 ; R a , at each occurrence, is selected from =0, OH, Cl, F, Cι_ 4 alkyl, (CH 2 ) r NR 2 R a , (CH 2 ) r C (0) R 2b , NR 2 C(0)R 2b , C(0)NR 2 R 2a , CH(=NH)NH 2 , NHC(=NH)NH 2 , S0 2 NR 2 R 2a , NR 2 S0 -Cι_ alkyl, NR 2 S0 2 R 5 , S(0) P R 5 , (CF 2 ) r CF 3 , and l-CF 3 -tetrazol-2-yl; R 5 , at each occurrence, is selected from CF 3 , C]__ 6 alkyl, phenyl substituted with 0-2 R 6 , and benzyl substituted with 0-2 R 6 ; R 6 , at each occurrence, is selected from H, =0, OH, OR 2 , Cl, F, CH 3 , CN, N0 2 , (CH 2 ) r NR 2 R 2 , (CH 2 ) r C (0) R 2b , NR 2 C(0)R 2b , CH(=NH)NH 2/ NHC(=NH)NH 2 , and S0 2 NR 2 R 2a ; R 7 , at each occurrence, is selected from H, OH, Cχ- 6 alkyl, Cι_ 6 alkylcarbonyl , Cχ_ 6 alkoxy, Cι_ 4 alkoxycarbonyl, benzyl, Cs-io aryloxy, C δ -io aryloxycarbonyl , C 6 - 10 arylmethylcarbonyl, C 1 -. 4 alkylcarbonyloxy C 1 -. 4 alkoxycarbonyl, C δ -io arylcarbonyloxy Cχ_ 4 alkoxycarbonyl, C 1 - 6 alkylaminocarbonyl , phenylaminocarbonyl , and phenyl Cχ_ 4 alkoxycarbonyl ; R 8 , at each occurrence, is selected from H, Cι_ 6 alkyl and benzyl ; and alternatively, R 7 and R 8 combine to form a morpholino group; and, R 9 , at each occurrence, is selected from H, Cι_ 6 alkyl and benzyl . [13] In a another further preferred embodiment, the present invention provides novel compounds of formulae la-lb, wherein; E is phenyl substituted with R or 2-pyridyl substituted with R; R is selected from H, Cl, F, 0CH 3 , CH 3 , OCF 3 , and CF 3 ; Z is selected from a C(0)CH 2 and C(0)NH, provided that Z does not form a N-N bond with group A; R la , at each occurrence, is selected from H, CH 3 , CH 2 CH 3 , Cl, F, CF 3 , OCH 3 , NR 2 R 2 , S(0) p R 2b , CH 2 S(0) p R 2b , CH 2 NR 2 S(0) p R 2b , C(0)R 2c , CH 2 C(0)R 2c , C(0)NR 2 R 2a , and S0 2 NR 2 R 2a ; R lb is selected from H, CH 3 , CH 2 CH 3 , Cl, F, CF 3 , OCH 3 , NR 2 R 2a , S(0) p R 2b , CH 2 S(0) p R 2 , CH 2 NR 2 S(0) p R 2b , C(0)R 2c , CH 2 C(0)R 2c , C(0)NR 2 R 2 , and S0NR 2 R 2a ; RI C i s selected from H, CH 3 , CH 2 CH 3 , CF 3 , CH 2 S(0) p R 2b , CH 2 NR 2 S(0) p R 2b , C(0)R 2c , CH 2 C(0)R 2c , and C(0)NR 2 R 2a ; A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ; phenyl, pyridyl, pyrimidyl, furanyl, thiophenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, and imidazolyl; B is selected from: Y and X-Y; X is selected from CH 2 , -CR 2 (CR 2 R 2b ) -, -C(O)-, -C(=NR)-, -CH(NR 2 R 2a )-, -C(0)NR 2 -, -NR 2 C(0)-, -NR 2 C (O)NR 2 - , -NR 2 -, and O; Y is NR 2 R 2a , provided that X-Y do not form a N-N or 0-N bond; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4a ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl , thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3-oxadiazolyl, 1,2, 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1, 2 , 4-thiadiazolyl, 1,2 , 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2 , 3-triazolyl, 1,2, 4-triazolyl, 1, 2 , 5-triazolyl, and 1, 3 , 4-triazolyl; R 2 , at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl ; R 2a , at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl ; R 2b , at each occurrence, is selected from CF 3 , OCH 3 , CH 3 , benzyl , and phenyl ; R 2c , at each occurrence, is selected from CF 3 , OH, OCH 3 , CH 3 , benzyl, and phenyl; alternatively, R 2 and R a combine to form a 5 or 6 membered saturated, partially unsaturated, or unsaturated ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S; R 3 , at each occurrence, is selected from H, CH 3 , CH 2 CH 3 , and phenyl ; R 3a , at each occurrence, is selected from H, CH 3 , CH 2 CH 3 , and phenyl ; R 4 , at each occurrence, is selected from OH, Cl, F, CH 3 , CH 2 CH 3 , NR 2 R 2a , CH 2 NR 2 R 2 , C(0)R 2b , NR 2 C(0)R 2b , C(0)NR 2 R 2a , and CF 3 ; R 4a , at each occurrence, is selected from OH, Cl, F, CH 3 , CH 2 CH 3 , NR 2 R 2a , CH 2 NR 2 R 2 , C(0)R 2b , C(0)NR 2 R a , S0 2 NR 2 R 2a , S(0) p R 5 , CF 3 , and l-CF 3 -tetrazol-2-yl; R 5 , at each occurrence, is selected from CF 3 , Cι_ 6 alkyl, phenyl substituted with 0-2 R 6 , and benzyl substituted with 1 R 6 ; R 6 , at each occurrence, is selected from H, OH, OCH 3 , Cl, F, CH 3 , CN, N0 2 , NR 2 R 2a , CH 2 NR 2 R a , and S0NR 2 R 2a ; R 7 , at each occurrence, is selected from H, OH, C 1 - 3 alkyl, Cι_ 3 alkylcarbonyl , Cχ_ 3 alkoxy, C 1 -. 4 alkoxycarbonyl, benzyl, phenoxy, phenoxycarbonyl, benzylcarbonyl , C 1 -. 4 alkylcarbonyloxy Cχ_ 4 alkoxycarbonyl, phenylcarbonyloxy Cι_ 4 alkoxycarbonyl, Cι_ 6 alkylaminocarbonyl, phenylaminocarbonyl , and phenyl C 1 -. 4 alkoxycarbonyl; R 8 , at each occurrence, is selected from H, CH 3 , and benzyl,- and, alternatively, R 7 and R 8 combine to form a morpholino group; R 9 , at each occurrence, is selected from H, CH 3 , and benzyl. [14] In a another still further preferred embodiment, the present invention provides novel compounds of formulae la-lb, wherein; R la , at each occurrence, is selected from H, CH 3 , CH 2 CH 3 , Cl, F, CF 3 , OCH 3 , NR 2 R 2a , S(0) p R 2b , C(0)NR 2 R 2a , CH 2 S(0) p R 2b , CH 2 NR 2 S(0) p R 2b , C(0)R 2c , CH 2 C(0)R 2 , and S0 2 NR 2 R 2a ; R ib Ξ selected from H, CH 3 , CHCH 3 , Cl, F, CF 3 , OCH 3 , NR 2 R 2a , S(0) p R 2b , C(0)NR 2 R 2a , CH 2 S(0) p R 2b , CH 2 NR 2 S (0) p R 2b , C(0)R 2b , CH 2 C(0)R 2b , and S0 2 NR 2 R 2a ; R lc is selected from H, CH 3 , CH 2 CH 3 , CF 3 , C(0)NR 2 R 2a , CH 2 S(0) p R 2b , CH 2 NR 2 S(0) p R 2b , C(0)R 2b , and CH 2 C(0)R 2b ; A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ; phenyl, pyridyl, and pyrimidyl; B is selected from: Y and X-Y; X is selected from -C(O)- and O; Y is NR 2 R 2a , provided that X-Y do not form a 0-N bond; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4a ; phenyl, piperazinyl, pyridyl, pyrimidyl, morpholinyl, pyrrolidinyl, imidazolyl, and 1,2,3- triazolyl ; R 2 , at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl; R 2a , at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl; R 2b , at each occurrence, is selected from CF 3 , OCH 3 , CH 3 , benzyl, and phenyl; R 2c , at each occurrence, is selected from CF 3 , OH, OCH 3 , CH 3 , benzyl, and phenyl; alternatively, R 2 and R 2a combine to form a ring system selected from pyrrolidinyl, piperazinyl and morpholino; R 4 , at each occurrence, is selected from Cl, F, CH 3 , NR 2 R 2a , and CF 3 ; R a , at each occurrence, is selected from Cl, F, CH 3 , S0NR 2 R 2a , S(0) p R 5 , and CF 3 ; and, R 5 , at each occurrence, is selected from CF 3 and CH 3 . [15] Specifically preferred compounds of the present invention are selected from the group: 1- (3-amidinophenyl) -5- [ [ (2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) -aminocarbony1] -3-trifluoromethyl-pyrazoline; and, 1- (3-aminomethylphenyl) -5- [ [ (2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) -aminocarbonyl] -3-trifluoromethyl-pyrazoline; and pharmaceutically acceptable salts thereof. In a second embodiment, the present invention provides novel pharmaceutical compositions, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt form thereof. In a third embodiment, the present invention provides a novel method for treating or preventing a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt form thereof . DEFINITIONS The compounds herein described may have asymmetric centers . Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms . It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. The term "substituted, " as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substitent is keto (i.e., =0), then 2 hydrogens on the atom are replaced. When any variable (e.g., R>) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R 6 , then said group may optionally be substituted with up to two R 6 groups and R 6 at each occurrence is selected independently from the definition of R 6 . Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds . As used herein, "Cι_ 6 alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, examples of which include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, pentyl, and hexyl; "Alkenyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, and the like. "Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, and iodo; and "counterion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate, and the like. As used herein, "carbocycle" or "carbocyclic residue" is intended to mean any stable 3- to 7-membered monocyclic or bicyclic or 7- to 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4. O]bicyclodecane (decalin) , [2.2.2] bicyclooctane, fluorenyl , phenyl , naphthyl , indanyl , adamantyl, or tetrahydronaphthyl (tetralin) . As used herein, the term "heterocycle" or "heterocyclic system" is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic ring which is saturated partially unsaturated or unsaturated (aromatic) , and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, 0 and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and 0 atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1. As used herein, the term "aromatic heterocyclic system" is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and from 1 to 4 heterotams independently selected from the group consisting of N, 0 and S. It is preferred that the total number of S and 0 atoms in the aromatic heterocycle is not more than 1. Examples of heterocycles include, but are not limited to, lH-indazole, 2-pyrrolidonyl, 2H, 6H-1, 5, 2-dithiazinyl, 2H- pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H- quinolizinyl, 6H-1, 2 , 5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl , benzothiofuranyl, benzothiophenyl , benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aff-carbazolyl , β-carbolinyl , chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H, 6H- 1,5,2-dithiazinyl , dihydrofuro [2,3 -b] tetrahydrofuran, furanyl , furazanyl, imidazolidinyl , imidazolinyl, imidazolyl, 1H- indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, isobenzofuranyl , isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl , octahydroisoquinolinyl, oxadiazolyl, 1, 2 , 3-oxadiazolyl, 1, 2 , 4-oxadiazolyl, 1,2,5- oxadiazolyl, 1, 3 , 4-oxadiazolyl, oxazolidinyl . , oxazolyl, oxazolidinylperimidinyl, phenanthridinyl, phenanthrolinyl , phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, piperidonyl, 4-piperidonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl , quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, carbolinyl, tetrahydrofuranyl , tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1, 2,5- thiadiazinyl, 1, 2 , 3-thiadiazolyl, 1, 2 , 4-thiadiazolyl, 1,2,5- thiadiazolyl, 1, 3 , 4-thiadiazolyl, thianthrenyl , thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1, 2 , 3 -triazolyl, 1, 2 , 4-triazolyl, 1, 2 , 5-triazolyl, 1, 3 , 4-triazolyl, xanthenyl . Preferred heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, indolyl, benzimidazolyl, lH-indazolyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, or isatinoyl . Also included are fused ring and spiro compounds containing, for example, the above heterocycles. The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio . As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic , phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like . The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington ' s Pharmaceutical Sciences, 17th ed. , Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference. "Prodrugs" are intended to include any covalently bonded carriers which release the active parent drug according to formula (I) in vivo when such prodrug is administered to a mammalian subject. Prodrugs of a compound of formula (I) are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. Prodrugs include compounds of formula (I) wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug or compound of formula (I) is administered to a mammalian subject, cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of formula (I) , and the like. Preferred prodrugs are amidine prodrugs wherein D is C(=NR 7 )NH 2 or its tautomer C(=NH)NHR 7 and R 7 is selected from OH, Cι- 4 alkoxy, Cβ-io aryloxy, C 1 -. 4 alkoxycarbonyl, C 6 _ιo aryloxycarbonyl , Cβ-io arylmethylcarbonyl , C 1 -. 4 alkylcarbonyloxy Cχ_ 4 alkoxycarbonyl, and C 6 - 10 arylcarbonyloxy C 1 - 4 alkoxycarbonyl. More preferred prodrugs are where R 7 is OH, methoxy, ethoxy, benzyloxycarbonyl, methoxycarbonyl , and methylcarbonyloxymethoxycarbonyl . "Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent . SYNTHESIS The compounds of the present invention can be prepared in a number of ways known to one skilled in the art of organic synthesis . The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention. It will also be recognized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention. An authoritative account describing the many alternatives to the trained practitioner is Greene and Wuts (Protective Groups In Organic Synthesis, Wiley and Sons, 1991) . All references cited herein are hereby incorporated in their entirety herein by reference. Pyrazolines of this invention can be easily prepared via [3+2] cycloaddition of bromo or chloro hydrazone with an appropriate acrylate according to the methodology described by Tewari R. S. and Parihar Tetrahedron 1983, 39, 129-136, or Krayushkin, M. M. et . al Izv. Akad. Nauk, Ser . Khim . 199 A , 1 , 114-117. Pyrazoline 5-esters can also be prepared by the treatment of an appropriately substituted hydrazone with lead tetraacetate and an appropriate acrylate in a THF/benzene solvent system according to the procedure of Sasaki T, et. al. Bull . Chem Soc . Jpn . 1970, 43 , 1254. Another method of obtaining pyrazoline 5-esters is the condensation of an appropriate phenyl or heteroaryl hydrazine with an approptiate 2-oxoglutaconate according to Blitzke, T. et. al. J. Prakt . Chem . 1993, 335 (8) , 683. Alternatively the pyrazoline ester can be prepared by treatment of a diazo-trifluoromethyl derivative with excess acrylate or acrolein in the presence of excess pyridine (Doyle, M. 0. et . al . J. Heterocyclic Chem. 1983, 20, 943) . Cycloadditions as described above but with di-substituted olefins should result in the formation of regio-adducts which can be easily separated by standard chromatographic techniques . It is understood by those in the art of organic synthesis that such cycloadditions can also be carried out with a wide variety of electron withdrawing olefins with functionalities such as nitro, sulfonyl, sulfonamido, nitrile, phosphate etc. These in turn can be derivatized to appropriate compounds of the present invention. The pyrazoline carboxyesters obtained via any of the above mentioned methodologies can be converted to the amide derivatives via the acid, acid chloride coupling methodlogies or a direct Weinreb (trimethylaluminum, aniline in dichloromethane) coupling technique known to those in the art of organic synthesis . A variety of anilines or amines can be coupled via these methodologies to afford the desired compounds . Alternatively the ester can be hydrolysed and converted to an amino functionality via the Curtius rearrangement. This in turn can be derivatised to obtain an amido, sulfonamido or urea derivative. Pyrazolines wherein s is other than 0 can be prepared by alkylation of an appropriate pyrazoline. The electrophile can consist of simple alkyl halides to heteroaryl alkyl halides . Some of the heteroaryl alkyl groups can include pyridyl, pyrimidyl, imidazolyl etc. In cases wherein D is a nitrile can be further converted to an amidine functionality via the standard Pinner-amidine reaction sequence known to those in the art or can be converted to the benzylamine via reduction in an acidic media or can be converted to the secondary and tertiary amine via the DIBAH/MeMgCl or MeMgBr/CeCl 3 methodologies outlined below. Compounds wherein D is a nitro can be reduced under catalytic Pd/C/MeOH techniques or SnCl 2 /EtOAc or Zn/AcOH conditions to afford the desired amino derivatives. Enantiomers of the pyrazolines can be easily obtained either via lipase hydrolysis of its esters or resolution with common chiral bases known to those in the art . 1, 2 , 3-Triazolines can be synthesized via the cycloaddition methodology however in this case the dipole is an aryl azide and the dipolarophile is a variety of olefins bearing an electron withdrawing group such as an ester, amide or sulfonamide. + regioisomer 1, 2 , 4-Triazolines can be prepared via the methods of Sandhy J. S. et. al . Heterocycles 1985, 23 (5) , 1143, and Heterocycles 1985, 23 (5) , 1123, by the method described in the scheme below. The triazoline esters can then subjected to the standard coupling procedures discussed above to afford the desired amide analogs. These can then further modified to the prepare compounds of the present invention. Compounds of the present invention wherein AB is a biphenylamine or similar amine may be prepared as shown in the following scheme. 4-Bromoaniline can be protected as Boc- derivative and coupled to a phenylboronic acid under Suzuki conditions (Bioorg. Med. Chem . Lett . 1994, 189) . Deprotection with TFA provides the aminobiphenyl compound. Other similar amines wherein A and/or B are heterocycles can be prepared by the same method using appropiately substituted boronic acids and arylbromide. The bromoaniline can also be linked to the core ring structures first as described above, and then undergo a Suzuki reaction to give the desired product . Compounds of the present invention wherein A-B is A-X-Y can be prepared like the piperazine derivative shown below. The following scheme shows how one can couple cyclic groups wherein X=NH, O, or S. reduction Halo Base, DMF X = NH, 0, S When B is defined as X-Y, the following description applies . Groups A and B are available either through commercial sources, known in the literature or readily synthesized by the adaptation of standard procedures known to practioners skilled in the art of organic synthesis. The required reactive functional groups appended to analogs of A and B are also available either through commercial sources, known in the literature or readily synthesized by the adaptation of standard procedures known to practioners skilled in the art of organic synthesis . In the tables that follow the chemistry required to effect the coupling of A to B is outlined. Table A: Preparation of Amide, Ester, Urea, The chemistry of Table A can be carried out in aprotic solvents such as a chlorocarbon, pyridine, benzene or toluene, at temperatures ranging from -20 C to the reflux point of the solvent and with or without a trialkylamine base. Table B: Preparation of ketone linkages between A and B. The coupling chemistry of Table B can be carried out by a variety of methods . The Grignard reagent required for Y is prepared from a halogen analog of Y in dry ether, dimethoxyethane or tetrahydrofuran at 0 C to the reflux point of the solvent. This Grignard reagent can be reacted directly under very controlled conditions, that is low temeprature (- 20 C or lower) and with a large excess of acid chloride or with catalytic or stoichiometric copper bromide*dimethyl sulfide complex in dimethyl sulfide as a solvent or with a variant thereof. Other methods available include transforming the Grignard reagent to the cadmium reagent and coupling according to the procedure of Carson and Prout (Org. Syn. Col. Vol. 3 (1955) 601) or a coupling mediated by Fe(acac)3 according to Fiandanese et al . (Tetrahedron Lett., (1984) 4805) , or a coupling mediated by manganese (II) catalysis (Cahiez and Laboue, Tetrahedron Lett., 33(31), (1992) 4437). Table C: Preparation of ether and thioether linkages between A and B The ether and thioether linkages of Table C can be prepared by reacting the two components in a polar aprotic solvent such as acetone, dimethylforma ide or dimethylsulfoxide in the presence of a base such as potassium carbonate, sodium hydride or potassium t-butoxide at temperature ranging from ambient temperature to the reflux point of the solvent used. Table D: Preparation of -SO- and -S02- linkages from The thioethers of Table C serve as a convenient starting material for the preparation of the sulfoxide and sulfone analogs of Table D. A combination of wet alumina and oxone can provide a reliable reagent for the oxidation of the thioether to the sulfoxide while m-chloroperbenzoic acid oxidation will give the sulfone. Table E: Methods of Preparing Group E Rxn D is to be then a transformation that may be used is NH 2 -CN -C ( =NH) NH2 i) HC1 MeOH / :N ii) NH 3 OAc, MeOH NH -CN -CH2NH2 LiAlH, :N ■ CH 2 NH 2 -C02H -CH2NH2 i) iBuOC(O)Cl -C02H -NH2 i) iBuOC(O)Cl NMM, THF then NaN 3 and heat ■ NH 2 ii) tBuOH, reflux OH ϋi)HCl, Et 2 O In Table E several methods of transforming a functional group Q into group D of Formula 1 are shown. While not all possible functional groups for Q and D are listed and the synthetic methods suggested are not comprehensive. Table E is meant to illustrate strategies and transformations available to a practitioner skilled in the art of organic synthesis for preparing compounds of Formula 1. In reaction 1 of Table E the transformation of a nitrile into an amidine by the Pinner methodology is shown; in reaction 2 the direct reduction of a nitrile by a hydride reducing agent to a methylene amine is illustrated. In reaction 3, the utility of a carboxylic acid, which may be readily derived from its ester or a nitrile if necessary, in the preparation of a methylene amine is shown. This synthetic route is exceptionally flexible because of the several stable intermediates prepared en route to the final product. As outlined, formation of an activated analog, such as the mixed anhydride, allows for the mild reduction of the acid to the methylene alcohol, this may in turn be transformed into a leaving group by sulfonylation or halogenation or protected with a suitable protecting group to be transformed later in the synthesis as the chemistry demands . Once the methylene alcohol is so activated, displacement by an efficient nitrogen nucleophile, such as azide anion, can again provide another suitably stable analog, -the methylene azide- which may be used as a protected form of the methylene amine or transformed directly into the methylene amine group by reduction. Reaction 4 addresses the problem of appending the amine functionality directly through a bond to group E of Formula 1. Once again, the carboxylic acid provides a convenient eπtre into this selection for group D. The well- know Curtius rearrangement is illustrated here; an activated acid analog can be used to form an acyl azide which upon thermal decomposition is rearranged to the corresponding isocyanate. The isocyanate intermediate may then be captured as a stable carbamate by the addition of a suitable alcohol and further heating. This carbamate can be used as a stable protecting group for the amine or cleaved directly to the desired D. Alternatively, it may be convenient to quench the isocyanate intermediate with water to give the amine directly. One diastereomer of a compound of Formula I may display superior activity compared with the others. Thus, the following stereochemistries are considered to be a part of the present invention. Iai Ia 2 Ibi Ib 2 ICi IC2 When required, separation of the racemic material can be achieved by HPLC using a chiral column or by a resolution using a resolving agent such as camphonic chloride as in Steven D. Young, et al, Antimicrobial Agents and Chemotheraphy, 1995, 2602-2605. A chiral compound of Formula I may also be directly synthesized using a chiral catalyst or a chiral ligand, e.g., Andrew S. Thompson, et al, Tet. lett. 1995, 36, 8937-8940) . Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof. EXAMPLES Examples 1 and 2 1- (3 -Amidinophenyl) -5- [ [ (2 ' -methylsulfonyl- [1,1']- biphen-4-yl) -aminocarbonyl] -3-trif luoromethyl- pyrazoline and 1- (3-aminomethylphenyl) -5- [[ (2 ' - methylsulfonyl- [1, 1 • ] -biphen-4-yl) -aminocarbonyl] -3- trif luoromethyl-pyrazoline Part A: To a methanolic solution containing meta-cyanophenyl- hydrazine (2 g, 15.03 mol) was added trifluoromethylacetaldehyde hydrate (1.74 g, 15.03 mmol) . The reaction mixture was heated to gentle reflux overnight. Methanol was stripped off to afford yellow crystals of pure hydrazone (2.99g, 93%) . 1 HNMR (CDCl 3 )δ: 10.10 (bs, 1H) , 7.33 (m, 2H) , 7.10 (m, 2H) ppm; ESI (-ve) mass spectrum analysis m/z (relative intensity) 212 (M-H, 100) . Part B: NCS (1.02 g, 7.69 mmol) was added to a DMF (25 mL) solution of the compound prepared in part A (1.64 g, 7.69 mmol) . The reaction mixture was stirred at room temperature over night, quenched with water (500 mL) and organics extracted with ethyl acetate (2x100 mL) dried (MgS0 4 ) and evaporated to a reddish brown oil . The oil was redissolved in chloroform (25 mL) and to this solution was added ethyl acrylate (10 mL) followed by slow addition of triethylamine (0.81 mL, 5.75 mmoL) . The reaction mixture was refluxed for 18h cooled and quenched with dil. hydrochloric acid (IN, 20 mL) . The organic layer was separated and evaporated to an oil. Chromatography on silica gel (7:3, Hexane:ethylacetate) afforded a colorless oil which solidified on standing (1.5 g, 62%). 1 HNMR(CDCl 3 )δ: 7.40-7.22 (m, 4H) , 4.89 (dd, J = 6.2 and 13.4Hz, 1H) , 4.24 (q, 2H) , 3.63-3.50 (dd, J = 1.9 and 13.2Hz, 1H) , 3.38 (dd, J = 1.9 and 14Hz, 1H) , 1.23 (t, 3H) ppm; ESI mass spectrum analysis m/z (relative intensity) 312 (M+H, 100) . Part C: The product from part B was treated with 2 ' - methylsulfonyl-4-amino- [1, 1' ]biphenyl under Weinreb conditions (trimethylaluminum in dichloromethane) to afford pure coupled product (oil) after silica gel column chromatography (hexane: ethyl acetate 7:3). 1 HNMR (CDC1 3 ) δ: 8.40 (bs, IH) , 8.17 (dd, J = 1.1 and 7.8Hz, IH) , 7.65-7.25 ( , 11H) , 4.90 (m, IH) , 3.78 (m, IH) , 3.38 (dd, J = 1.5 and 8.1Hz, IH) , 2.69 s, 3H) ; ESI (-ve) mass spectrum analysis m/z (rel. intensity) 511 (M- H, 100) . Part D: The product from part C was subjected to the Pinner amidine reaction sequence (HCl/MeOH followed by ammonium carbonate in methanol) , purified via standard HPLC purification, lyophilization to afford (40% yield) of Example 1 as colorless crystals. X HΝMR (DMS0 6 ) δ: 9.36 (bs, 1.5H), 9.00 (bs, 1.5Hz), 8.06 (d, J = 7.7Hz, IH) , 7.53-7.78 (m, 6H) , 7.35 (d, J = 8.1Hz, 3H) , 7.27 (d, J = 8.0Hz, IH) , 7.17 (d, J = 8.5Hz, IH) , 5.33 (dd, J = 6.2 and 13.2Hz, IH) , 3.76 (t, IH) , 3.40 (d, J = 3.1Hz, IH) , 2.84(s, 3H) ppm; ESI (+ve) mass spectum analysis m/z (relative intensity) 530 (M+H, 100) . Additionally, the compound form Part C was subjected to reduction using 10% Pd/C in an acidic medium (methanol/acetic acid) . Purification via standard HPLC techniques and lyophilization afforded the benzylamine (10% yield) . 1 HNMR(DMS0 6 )δ: 8.07 (bs, 2H) , 8.01 (d, J = 8Hz, IH) , 7.70 (m, IH) , 7.59 (m, 3H) , 7.28 (m, 4H) , 6.95 (d, J = 8Hz, IH) , 6.83 (dd, J = 1/5 and 8Hz, IH) , 6.40 (bs, 2H) , 5.22 (dd, J = 6.5 and 13Hz, IH) , 4.00 (m, IH) , 3.71 (m, IH) , 3.34 (dd, J = 1.5 and 8Hz, IH) , 2.84 (s, 3H) ppm; ESI mass spectrum analysis m/z (relative intensity) 517 (M+H, 100) . The following tables contain representative examples of the present invention. Each entry in each table is intended to be paired with each formulae at the start of the table. For example, in Table 1, example 1 is intended to be paired with each of formulae a-ttt and in Table 2, example 1 is intended to be paired with each of formulae a-ss . The following groups are intended for group A in the following tables . 2-pyrιdyl 3-pyrιdyl 2-pyrιmιdyl »^Q-< 3 -™-\ )- B _H - - B 5-pyrιmιdyl 2-CI-phenyl 2-F-phenyl 2,6-dιF-phenyl Table 1 ' j m w aa bb hh gg kk oo PP qq tt rr ss xx zz yy ggg hhh JJJ kkk m m sss ttt # l i e B CH 3 phenyl 2- (aminosulfonyl ) phenyl CH 3 phenyl 2 - (methylammosulf onyl ) phenyl CH 3 phenyl 1 -pyrr o 1 idinocarbony 1 CH 3 phenyl 2- (methylsulfonyl ) phenyl CH 3 phenyl 4 -morpholino CH 3 phenyl 2- ( 1 ' -CF3 -tetrazol -2 -yl ) phenyl CH 3 phenyl 4-morpholinocarbonyl CH 3 phenyl 2-methyl-l-imidazolyl CH 3 phenyl 5 -methyl -1- imidazolyl CH 3 phenyl 2 -methylsulfonyl-1- imidazolyl CH 3 2-pyridyl 2 - ( aminosulfonyl ) phenyl CH 3 2-pyridyl 2 - (methylammosulf onyl ) phenyl CH 3 2-pyridyl 1-pyrrolidinocarbonyl CH 3 2-pyridyl 2- (methylsulfonyl ) phenyl CH 3 2-pyridyl 4 -morpholino CH 3 2-pyridyl 2- ( 1 ' -CF3 -tetrazol -2 -yl) phenyl CH 3 2-pyridyl 4 -morpholinocarbonyl CH 3 2-pyridyl 2-methyl-l-imidazolyl CH 3 2-pyridyl 5-methyl-1-imidazolyl CH 3 2-pyridyl 2-methylsulfonyl-1-imidazolyl CH 3 3-pyridyl 2- (aminosulfonyl)phenyl CH 3 3-pyridyl 2- (methylammosulfonyl) phenyl CH 3 3-pyridyl 1-pyrro1idinocarbony1 CH 3 3-pyridyl 2- (methylsulfonyl)phenyl CH 3 3-pyridyl 4-morpholino CH 3 3-pyridyl 2- (1' -CF3-tetrazol-2-yl)phenyl CH 3 3-pyridyl 4-morpholinocarbonyl CH 3 3-pyridyl 2-methyl-l-imidazolyl CH 3 3-pyridyl 5-methyl-l-imidazolyl CH 3 3-pyridyl 2-methylsulfonyl-1-imidazolyl CH 3 2-pyrimidyl 2- (aminosulfonyl) phenyl CH 3 2-pyrimidyl 2- (methylammosulfonyl)phenyl CH 3 2-pyrimidyl 1-pyrrolidinocarbonyl CH 3 2-pyrimidyl 2- (methylsulfonyl)phenyl CH 3 2-pyrimidyl 4-morpholino CH 3 2-pyrimidyl 2- (1' -CF3-tetrazol-2-yl) phenyl CH 3 2-pyrimidyl 4-morpholinocarbonyl CH 3 2-pyrimidyl 2-methyl-l-imidazolyl CH 3 2-pyrimidyl 5-methyl-l-imidazolyl CH 3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl CH 3 5-pyrimidyl 2- (aminosulfonyl) phenyl CH 3 5-pyrimidyl 2- (methylammosulfonyl) phenyl CH 3 5-pyrimidyl 1-pyrro1idinocarbony1 CH 3 5-pyrimidyl 2- (methylsulfonyl) phenyl CH 3 5-pyrimidyl 4-morpholino CH 3 5-pyrimidyl 2- (1' -CF3-tetrazol-2-yl) phenyl CH 3 5-pyrimidyl 4-morpho1inocarbony1 CH 3 5-pyrimidyl 2-methyl-l-imidazolyl CH 3 5-pyrimidyl 5-methyl-l-imidazolyl CH 3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl CH 3 2-Cl-phenyl 2- (aminosulfonyl)phenyl CH 3 2-Cl-phenyl 2- (methylammosulfonyl)phenyl CH 3 2-Cl-phenyl 1-pyrrolidinocarbonyl CH 3 2-Cl-phenyl 2- (methylsulfonyl)phenyl CH 3 2-Cl-phenyl 4-morpho1ino CH 3 2-Cl-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl CH 3 2-Cl-phenyl 4-morpholinocarbonyl CH 3 2-Cl-phenyl 2-methyl-l-imidazolyl CH 3 2-Cl-phenyl 5-methyl-l-imidazolyl CH 3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl CH 3 2-F-phenyl 2- (aminosulfonyl) phenyl CH 3 2-F-phenyl 2- (methylammosulfonyl ) phenyl CH 3 2-F-phenyl 1-pyrrolidinocarbonyl CH 3 2-F-phenyl 2- (methylsulfonyl) phenyl CH 3 2-F-phenyl 4-morpholino CH 3 2-F-phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl CH 3 2-F-phenyl 4-morpholinocarbonyl CH 3 2-F-phenyl 2-methyl-l-imidazolyl CH 3 2-F-phenyl 5-methyl-l-imidazolyl CH 3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl CH 3 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl CH 3 2, 6-diF-phenyl 2- (methylammosulfonyl) phenyl CH 3 2, 6-diF-phenyl 1-pyrro1idinocarbony1 CH 3 2, 6-diF-phenyl 2- (methylsulfonyl ) phenyl CH 3 2, 6-diF-phenyl 4-morpholino CH 3 2, 6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl CH 3 2,6-diF-phenyl 4-morpholinocarbonyl CH 3 2, 6-diF-phenyl 2-methyl-l-imidazolyl CH 3 2, 6-diF-phenyl 5-methyl-l-imidazolyl CH 3 2 , 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl CH 2 CH 3 phenyl 2- (aminosulfonyl) phenyl CH 2 CH 3 phenyl 2- (methylaminosulfonyl) phenyl CH 2 CH 3 phenyl 1-pyrrolidinocarbonyl CH 2 CH 3 phenyl 2- (methylsulfonyl) phenyl CH 2 CH 3 phenyl 4-morpholino CH 2 CH 3 phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl CH 2 CH 3 phenyl 4-morpho1inocarbony1 CH 2 CH 3 phenyl 2-methyl-l-imidazolyl CH 2 CH 3 phenyl 5-methyl-l-imidazolyl CH 2 CH 3 phenyl 2-methylsulfonyl-l-imidazolyl CH 2 CH 3 2-pyridyl 2- (aminosulfonyl) phenyl 92 CH 2 CH 3 2-pyridyl 2- (methylaminosulfonyl)phenyl 93 CH 2 CH 3 2-pyridyl 1-pyrrolidinocarbonyl 94 CH 2 CH 3 2-pyridyl 2- (methylsulfonyl)phenyl 95 CH 2 CH 3 2-pyridyl 4-morpho1ino 96 CH 2 CH 3 2-pyridyl 2- (l'-CF3-tetrazol-2-yl)phenyl 97 CH 2 CH 3 2-pyridyl 4-morpholinocarbonyl 98 CH 2 CH 3 2-pyridyl 2-methyl-l-imidazolyl 99 CH 2 CH 3 2-pyridyl 5-methyl-l-imidazolyl 100 CH 2 CH 3 2-pyridyl 2-methylsulfonyl-l-imidazolyl 101 CH 2 CH 3 3-pyridyl 2- (aminosulfonyl)phenyl 102 CH 2 CH 3 3-pyridyl 2- (methylaminosulfonyl) phenyl 103 CH 2 CH 3 3-pyridyl 1-pyrrolidinocarbonyl 104 CH 2 CH 3 3-pyridyl 2- (methylsulfonyl) phenyl 105 CH 2 CH 3 3-pyridyl 4-morpho1ino 106 CHCH 3 3-pyridyl 2-(l' -CF3-tetrazol-2-yl)phenyl 107 CH 2 CH 3 3-pyridyl 4-morpholinocarbonyl 108 CH 2 CH 3 3-pyridyl 2-methyl-l-imidazolyl 109 CH 2 CH 3 3-pyridyl 5-methyl-l-imidazolyl 110 CH 2 CH 3 3-pyridyl 2-methylsulfonyl-l-imidazolyl 111 CH 2 CH 3 2-pyrimidyl 2- (aminosulfonyl)phenyl 112 CH 2 CH 3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 113 CH 2 CH 3 2-pyrimidyl 1-pyrro1idinocarbony1 114 CH 2 CH 3 2-pyrimidyl 2- (methylsulfonyl)phenyl 115 CH 2 CH 3 2-pyrimidyl 4-morpholino 116 CHCH 3 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl 117 CH 2 CH 3 2-pyrimidyl 4-morpho1inocarbony1 118 CH 2 CH 3 2-pyrimidyl 2-methyl-l-imidazolyl 119 CH 2 CH 3 2-pyrimidyl 5-methyl-l-imidazolyl 120 CH 2 CH 3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl 121 CH 2 CH 3 5-pyrimidyl 2- (aminosulfonyl) phenyl 122 CH 2 CH 3 5-pyrimidyl 2- (methylaminosulfonyl)phenyl 123 CH 2 CH 3 5-pyrimidyl 1-pyrrolidinocarbonyl 124 CH 2 CH 3 5-pyrimidyl 2- (methylsulfonyl)phenyl 125 CH 2 CH 3 5-pyrimidyl 4-morpho1ino 126 CH 2 CH 3 5-pyrimidyl 2- (1' -CF3-tetrazol-2-yl)phenyl 127 CH 2 CH 3 5-pyrimidyl 4-morpholinocarbonyl 128 CH 2 CH 3 5-pyrimidyl 2-methyl-l-imidazolyl 129 CH 2 CH 3 5-pyrimidyl 5-methyl-1-imidazolyl 130 CH 2 CH 3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl 131 CH 2 CH 3 2-Cl-phenyl 2- (aminosulfonyl) phenyl 132 CH 2 CH 3 2-Cl-phenyl 2- (methylaminosulfonyl ) phenyl 133 CH 2 CH 3 2-Cl-phenyl 1-pyrrolidinocarbonyl 134 CH 2 CH 3 2 -Cl-phenyl 2- (methylsulfonyl ) henyl 135 CH2CH3 2-Cl-phenyl 4-morpholino 136 CHCH 3 2-Cl-phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl 137 CH 2 CH3 2-Cl-phenyl 4-morpholinocarbonyl 138 CH 2 CH 3 2-Cl-phenyl 2-methyl-l-imidazolyl 139 CH2CH3 2-Cl-phenyl 5-methyl-l-imidazolyl 140 CH2CH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl 141 CH2CH3 2 -F-phenyl 2- (aminosulfonyl ) phenyl 142 CH 2 CH 3 2 -F-phenyl 2- (methylaminosulfonyl ) phenyl 143 CH 2 CH 3 2-F-phenyl 1-pyrrolidinocarbonyl 144 CH 2 CH 3 2-F-phenyl 2- (methylsulfonyl ) phenyl 145 CH 2 CH 3 2-F-phenyl 4-morpholino 146 CH 2 CH 3 2-F-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl 147 CH 2 CH 3 2-F-phenyl 4-morpho1inocarbony1 148 CH2CH3 2-F-phenyl 2-methyl-1-imidazolyl 149 CH 2 CH 3 2-F-phenyl 5-methyl-l-imidazolyl 150 CH 2 CH 3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl 151 CH 2 CH 3 2, , 6-diF-phenyl 2- (aminosulfonyl) phenyl 152 CH 2 CH 3 2, , 6-diF-phenyl 2 - (methylaminosulfonyl ) phenyl 153 CH 2 CH 3 2, , 6-diF-phenyl 1-pyrrolidinocarbonyl 154 CH 2 CH 3 2, , 6-diF-phenyl 2- (methylsulfonyl ) phenyl 155 CH 2 CH 3 2, .6-diF-phenyl 4-morpholino 156 CH 2 CH 3 2, , 6-diF-phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 157 CH 2 CH 3 2, , 6-diF-phenyl 4-morpho1inocarbony1 158 CH 2 CH 3 2, 6-diF-phenyl 2-methyl-l-imidazolyl 159 CH 2 CH 3 2, 6-diF-phenyl 5-methyl-l-imidazolyl 160 CH 2 CH 2, 6-diF-ohenyl 2-methylsulfonyl-l-imidazolyl 161 CF 3 phenyl 2- (aminosulfonyl ) phenyl 162 CF3 phenyl 2- (methylaminosulfonyl) phenyl 163 CF3 phenyl 1-pyrrolidinocarbonyl 164 CF3 phenyl 2- (methylsulfonyl ) phenyl 165 CF3 phenyl 4-morpholino 166 CF 3 phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl 167 CF 3 phenyl 4-morpholinocarbonyl 168 CF 3 phenyl 2-methyl-l-imidazolyl 169 CF 3 phenyl 5-methyl-l-imidazolyl 170 CF 3 phenyl 2-methylsulfonyl-l-imidazolyl 171 CF3 2-pyridyl 2- (aminosulfonyl) phenyl 172 CF3 2-pyridyl 2- (methylaminosulfonyl) phenyl 173 CF3 2-pyridyl 1-pyrrolidinocarbonyl 174 CF3 2-pyridyl 2- (methylsulfonyl) phenyl 175 CF3 2-pyridyl 4-morpholino 176 CF 3 2-pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl 177 CF3 2-pyridyl 4-morpholinocarbonyl 178 CF3 2-pyridyl 2-methyl-l-imidazolyl 179 CF3 2-pyridyl 5-methyl-l-imidazolyl 180 CF3 2-pyridyl 2-methylsulfonyl-l-imidazolyl 181 CF3 3-pyridyl 2- (aminosulfonyl) phenyl 182 CF3 3-pyridyl 2- (methylaminosulfonyl) phenyl 183 CF3 3-pyridyl 1-pyrrolidinocarbonyl 184 CF 3 3-pyridyl 2- (methylsulfonyl) phenyl 185 CF3 3-pyridyl 4-morpholino 186 CF 3 3-pyridyl 2- (1' -CF3-tetrazol-2-yl)phenyl 187 CF3 3-pyridyl 4-morpholinocarbonyl 188 CF 3 3-pyridyl 2-methyl-l-imidazolyl 189 CF 3 3-pyridyl 5-methyl-l-imidazolyl 190 CF3 3-pyridyl 2-methylsulfonyl-l-imidazolyl 191 CF 3 2-pyrimidyl 2- (aminosulfonyl) phenyl 192 CF 3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 193 CF 3 2-pyrimidyl 1-pyrrolidinocarbonyl 194 CF 3 2-pyrimidyl 2- (methylsulfonyl) phenyl 195 CF 3 2-pyrimidyl 4-morpho1ino 196 CF 3 2-pyrimidyl 2-(l'-CF3-tetrazol-2-yl)phenyl 197 CF 3 2-pyrimidyl 4-morpholinocarbony1 198 CF 3 2-pyrimidyl 2-methyl-l-imidazolyl 199 CF 3 2-pyrimidyl 5-methyl-l-imidazolyl 200 CF3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl 201 CF 3 5-pyrimidyl 2- (aminosulfonyl) henyl 202 CF3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 203 CF 3 5-pyrimidyl 1-pyrrolidinocarbonyl 204 CF 3 5-pyrimidyl 2- (methylsulfonyl ) phenyl 205 CF 3 5-pyrimidyl 4-morpholino 206 CF 3 5-pyrimidyl 2- ( l ' -CF3 -tetrazol-2-yl ) phenyl 207 CF 3 5-pyrimidyl 4-morpholinocarbonyl 208 CF 3 5-pyrimidyl 2-methyl-l-imidazolyl 209 CF 3 5-pyrimidyl 5-methyl-l-imidazolyl 210 CF 3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl 211 CF 3 2-Cl-phenyl 2- (aminosulfonyl) phenyl 212 CF 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 213 CF 3 2-Cl-phenyl 1-pyrro1idinocarbony1 214 CF 3 2-Cl-phenyl 2- (methylsulfonyl) phenyl 215 CF 3 2-Cl-phenyl 4-morpholino 216 CF 3 2-Cl-phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 217 CF 3 2-Cl-phenyl 4-morpholinocarbonyl 218 CF 3 2-Cl-phenyl 2-methyl-l-imidazolyl 219 CF 3 2-Cl-phenyl 5-methyl-l-imidazolyl 220 CF 3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl 221 CF 3 2-F-phenyl 2- (aminosulfonyl)phenyl 222 CF 3 2-F-phenyl 2- (methylaminosulfonyl) phenyl 223 CF 3 2-F-phenyl 1-pyrro1idinocarbony1 224 CF 3 2-F-phenyl 2- (methylsulfonyl) phenyl 225 CF 3 2-F-phenyl 4-morpho1ino 226 CF 3 2-F-phenyl 2- ( l ' -CF3 - tetrazol-2 -yD phenyl 227 CF 3 2-F-phenyl 4-morpholinocarbonyl 228 CF 3 2-F-phenyl 2-methyl-1-imidazolyl 229 CF 3 2-F-phenyl 5-methyl-l-imidazolyl 230 CF 3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl 231 CF 3 2 , 6-diF-phenyl 2- (aminosulfonyl) phenyl 232 CF 3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 233 CF 3 2 , 6-diF-phenyl 1-pyrro1idinocarbony1 234 CF 3 2 , 6-diF-phenyl 2- (methylsulfonyl) henyl 235 CF 3 2, 6-diF-phenyl 4-morpho1ino 236 CF 3 2, 6-diF-phenyl 2- (l'-CF3-tetrazol-2-yl)phenyl 237 CF 3 2 , 6-diF-phenyl 4-morpho1inocarbony1 238 CF 3 2 , 6-diF-phenyl 2-methyl-1-imidazolyl 239 CF 3 2, 6-diF-phenyl 5-methyl-l-imidazolyl 240 CF3 2,6-diF-phenyl 2-methylsulfonyl-l-imidazolyl 241 SCH3 phenyl 2- (aminosulfony1 ) phenyl 242 SCH3 phenyl 2- (methylaminosulfonyl) phenyl 243 SCH3 phenyl 1-pyrrolidinocarbonyl 244 SCH 3 phenyl 2- (methylsulfonyl ) phenyl 245 SCH3 phenyl 4-morpholino 246 SCH3 phenyl 2- (1' -CF3-tetrazol-2-yl)phenyl 247 SCH 3 phenyl 4-morpholinocarbonyl 248 SCH3 phenyl 2-methyl-l-imidazolyl 249 SCH3 phenyl 5-methyl-l-imidazolyl 250 SCH3 phenyl 2-methylsulfonyl-l-imidazolyl 251 SCH 3 2-pyridyl 2- (aminosulfonyl ) phenyl 252 SCH 3 2-pyridyl 2- (methylaminosulfonyl ) phenyl 253 SCH 3 2-pyridyl 1-pyrro1idinocarbony1 254 SCH 3 2-pyridyl 2- (methylsulfonyl ) phenyl 255 SCH 3 2-pyridyl 4-morpholino 256 SCH 3 2-pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl 257 SCH 3 2-pyridyl 4-morpholinocarbonyl 258 SCH 3 2-pyridyl 2-methyl-l-imidazolyl 259 SCH 3 2-pyridyl 5-methyl-l-imidazolyl 260 SCH 3 2-pyridyl 2-methylsulfonyl-l-imidazolyl 261 SCH 3 3-pyridyl 2- (aminosulfonyl) phenyl 262 SCH 3 3-pyridyl 2- (methylaminosulfonyl ) phenyl 263 SCH 3 3-pyridyl 1-pyrrolidinocarbonyl 264 SCH 3 3-pyridyl 2- (methylsulfonyl) phenyl 265 SCH 3 3-pyridyl 4-morpholino 266 SCH 3 3-pyridyl 2-(l'-CF3-tetrazol-2-yl)phenyl 267 SCH 3 3-pyridyl 4-morpho1inocarbony1 268 SCH 3 3-pyridyl 2-methyl-l-imidazolyl 269 SCH 3 3-pyridyl 5-methyl-l-imidazolyl 270 SCH 3 3-pyridyl 2-methylsulfonyl-l-imidazolyl 271 SCH 3 2-pyrimidyl 2- (aminosulfonyl ) phenyl 272 SCH 3 2-pyrimidyl 2- (methylaminosulfonyl ) phenyl 273 SCH 3 2-pyrimidyl 1-pyrrolidinocarbonyl 274 SCH 3 2-pyrimidyl 2- (methylsulfonyl ) phenyl 275 SCH 3 2-pyrimidyl 4-morpholino 276 SCH 3 2-pyrimidyl 2-(l'-CF3-tetrazol-2-yl)phenyl 277 SCH 3 2-pyrimidyl 4-morpholinocarbonyl 278 SCH 3 2-pyrimidyl 2-methyl-l-imidazolyl 279 SCH 3 2-pyrimidyl 5-methyl-l-imidazolyl 280 SCH 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl 281 SCH 3 5-pyrimidyl 2- (aminosulfonyl) phenyl 282 SCH 3 5-pyrimidyl 2- (methylaminosulfonyl)phenyl 283 SCH 3 5-pyrimidyl 1-pyrrolidinocarbonyl 284 SCH 3 5-pyrimidyl 2- (methylsulfonyl)phenyl 285 SCH 3 5-pyrimidyl 4-morpho1ino 286 SCH 3 5-pyrimidyl 2- ( l ' -CF3 - tetrazol-2 -yD phenyl 287 SCH 5-pyrimidyl 4-morpholinocarbonyl 288 SCH 3 5-pyrimidyl 2-methyl-l-imidazolyl 289 SCH 3 5-pyrimidyl 5-methyl-l-imidazolyl 290 SCH 3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl 291 SCH 3 2-Cl-phenyl 2- (aminosulfonyl)phenyl 292 SCH 3 2-Cl-phenyl 2- (methylaminosulfonyl)phenyl 293 SCH 3 2-Cl-phenyl 1-pyrrolidinocarbonyl 294 SCH 3 2-Cl-phenyl 2- (methylsulfonyl)phenyl 295 SCH 3 2-Cl-phenyl 4-morpho1ino 296 SCH 3 2-Cl-phenyl 2- (1' -CF3-tetrazol-2-yl)phenyl 297 SCH 3 2-Cl-phenyl 4-morpho1inocarbony1 298 SCH 3 2-Cl-phenyl 2-methyl-l-imidazolyl 299 SCH 3 2-Cl-phenyl 5-methyl-l-imidazolyl 300 SCH 3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl 301 SCH 3 2-F-phenyl 2- (aminosulfonyl)phenyl 302 SCH 3 2-F-phenyl 2- (methylaminosulfonyl)phenyl 303 SCH 3 2-F-phenyl 1-pyrro1idinocarbony1 304 SCH 3 2-F-phenyl 2- (methylsulfonyl) phenyl 305 SCH 3 2-F-phenyl 4-morpholino 306 SCH 3 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl 307 SCH 3 2-F-phenyl 4-morpholinocarbonyl 308 SCH 3 2-F-phenyl 2-methyl-l-imidazolyl 309 SCH 3 2-F-phenyl 5-methyl-l-imidazolyl 310 SCH 3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl 311 SCH 3 2 , 6-diF-phenyl 2- (aminosulfonyl)phenyl 312 SCH 3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 313 SCH 3 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl 314 SCH 3 2 , 6-diF-phenyl 2- (methylsulfonyl ) phenyl 315 SCH 3 2 , 6-diF-phenyl 4-morpholino 316 SCH 3 2, 6-diF-phenyl 2- ( l ' -CF3 - tetrazol-2 -yD phenyl 317 SCH 3 2, 6-diF-phenyl 4-morpholinocarbonyl 318 SCH 3 2 , 6-diF-phenyl 2-methyl-l-imidazolyl 319 SCH 3 2 , 6-diF-phenyl 5-methy1-1-imidazolyl 320 SCH 2 , 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl 321 SOCH 3 phenyl 2- (aminosulfonyl) phenyl 322 SOCH3 phenyl 2- (methylaminosulfonyl) phenyl 323 SOCH3 phenyl 1-pyrrolidinocarbonyl 324 SOCH3 phenyl 2- (methylsulfonyl) phenyl 325 SOCH3 phenyl 4-morpholino 326 SOCH 3 phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl 327 SOCH3 phenyl 4-morpholinocarbonyl 328 SOCH3 phenyl 2-methyl-l-imidazolyl 329 SOCH3 phenyl 5-methyl-l-imidazolyl 330 SOCH 3 phenyl 2-methylsulfonyl-l-imidazolyl 331 SOCH 3 2-pyridyl 2- (aminosulfonyl ) phenyl 332 SOCH 3 2-pyridyl 2- (methylaminosulfonyl) phenyl 333 SOCH 3 2-pyridyl 1-pyrrolidinocarbonyl 334 SOCH 3 2-pyridyl 2- (methylsulfonyl) phenyl 335 SOCH 3 2-pyridyl 4-morpholino 336 SOCH 3 2-pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl 337 SOCH3 2-pyridyl 4-morpholinocarbonyl 338 SOCH3 2-pyridyl 2-methyl-l-imidazolyl 339 SOCH 3 2-pyridyl 5-methyl-l-imidazolyl 340 SOCH 3 2-pyridyl 2-methylsulfonyl-l-imidazolyl 341 SOCH 3 3-pyridyl 2- (aminosulfonyl) phenyl 342 SOCH3 3-pyridyl 2- (methylaminosulfonyl) phenyl 343 SOCH 3 3-pyridyl 1-pyrrolidinocarbonyl 344 SOCH3 3-pyridyl 2- (methylsulfonyl)phenyl 345 SOCH3 3-pyridyl 4-morpholino 346 SOCH 3 3-pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl 347 SOCH3 3-pyridyl 4-morpholinocarbonyl 348 SOCH3 3-pyridyl 2-methyl-l-imidazolyl 349 SOCH 3 3-pyridyl 5-methyl-l-imidazolyl 350 SOCH3 3-pyridyl 2-methylsulfonyl-l-imidazolyl 351 SOCH 3 2-pyrimidyl 2- (aminosulfonyl)phenyl 352 SOCH 3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 353 SOCH 3 2-pyrimidyl 1-pyrrolidinocarbonyl 354 SOCH 3 2-pyrimidyl 2- (methylsulfonyl)phenyl 355 SOCH 3 2-pyrimidyl 4-morpholino 356 SOCH 3 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 357 SOCH 3 2-pyrimidyl 4-morpholinocarbonyl 358 SOCH 3 2-pyrimidyl 2-methyl-l-imidazolyl 359 SOCH 3 2-pyrimidyl 5-methyl-l-imidazolyl 360 SOCH 3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl 361 SOCH 3 5-pyrimidyl 2- (aminosulfonyl)phenyl 362 SOCH 3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 363 SOCH 3 5-pyrimidyl 1-pyrrolidinocarbony1 364 SOCH 3 5-pyrimidyl 2- (methylsulfonyl)phenyl 365 SOCH 3 5-pyrimidyl 4-morpholino 366 SOCH 3 5-pyrimidyl 2- (l'-CF3-tetrazol-2-yl)phenyl 367 SOCH 3 5-pyrimidyl 4-morpholinocarbonyl 368 SOCH 3 5-pyrimidyl 2-methyl-l-imidazolyl 369 SOCH 3 5-pyrimidyl 5-methyl-l-imidazolyl 370 SOCH 3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl 371 SOCH 3 2-Cl-phenyl 2- (aminosulfonyl) phenyl 372 SOCH 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 373 SOCH 3 2-Cl-phenyl 1-pyrrolidinocarbonyl 374 SOCH 3 2-Cl-phenyl 2- (methylsulfonyl) phenyl 375 SOCH 3 2-Cl-phenyl 4-morpho1ino 376 SOCH 3 2-Cl-phenyl 2- (1' -CF3-tetrazol-2-y phenyl 377 SOCH 3 2-Cl-phenyl 4-morpho1inocarbony1 378 SOCH 3 2-Cl-phenyl 2-methyl-l-imidazolyl 379 SOCH 3 2-Cl-phenyl 5-methyl-l-imidazolyl 380 SOCH 3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl 381 SOCH 3 2-F-phenyl 2- (aminosulfonyl) henyl 382 SOCH 3 2-F-phenyl 2- (methylaminosulfonyl) phenyl 383 SOCH 3 2-F-phenyl 1-pyrrolidinocarbonyl 384 SOCH 3 2-F-phenyl 2- (methylsulfonyl) phenyl 385 SOCH 3 2-F-phenyl 4-morpho1ino 386 SOCH 3 2-F-phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl 387 SOCH 3 2-F-phenyl 4-morpho1inocarbony1 388 SOCH 3 2-F-phenyl 2-methyl-l-imidazolyl 389 SOCH 3 2-F-phenyl 5-methyl-l-imidazolyl 390 SOCH 3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl 391 SOCH3 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl 392 SOCH 3 2, 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 393 SOCH 3 2 , 6-diF-phenyl 1-pyrro1idinocarbony1 394 SOCH 3 2, 6-diF-phenyl 2- (methylsulfonyl)phenyl 395 SOCH 3 2, 6-diF-phenyl 4-morpholino 396 SOCH3 2, 6-diF-phenyl 2- (1' -CF3-tetrazol-2-yl)phenyl 397 SOCH3 2, 6-diF-phenyl 4-morpholinocarbonyl 398 SOCH 3 2 , 6-diF-phenyl 2-methyl-l-imidazolyl 399 SOCH 3 2, 6-diF-phenyl 5-methyl-l-imidazolyl 400 SOCH 3 2, 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl 401 SO2CH 3 phenyl 2- (aminosulfonyl) phenyl 402 S0 2 CH 3 phenyl 2- (methylaminosulfonyl)phenyl 403 S0 2 CH 3 phenyl 1-pyrro1idinocarbony1 404 S0 2 CH 3 phenyl 2- (methylsulfonyl) henyl 405 SO2CH 3 phenyl 4-morpholino 406 SO2CH 3 phenyl 2-(l' -CF3-tetrazol-2-yDphenyl 407 S0 2 CH 3 phenyl 4-morpholinocarbonyl 408 S0 CH 3 phenyl 2-methyl-l-imidazolyl 409 S0 2 CH 3 phenyl 5-methyl-1-imidazolyl 410 S0 2 CH 3 phenyl 2-methylsulfonyl-l-imidazolyl 411 S0 CH 3 2-pyridyl 2- (aminosulfonyl) phenyl 412 SO2CH 3 2-pyridyl 2- (methylaminosulfonyl) phenyl 413 SO2CH3 2-pyridyl 1-py ro1idinocarbony1 414 SO2CH3 2-pyridyl 2- (methylsulfonyl) phenyl 415 S0 2 CH 3 2-pyridyl 4-morpholino 416 S0 2 CH 3 2-pyridyl 2-(l'-CF3-tetrazol-2-yl)phenyl 417 S0 2 CH 3 2-pyridyl 4-morpholinocarbonyl 418 S0 2 CH 3 2-pyridyl 2-methyl-l-imidazolyl 419 SO2CH3 2-pyridyl 5-methyl-l-imidazolyl 420 S0 2 CH 3 2-pyridyl 2-methylsulfonyl-l-imidazolyl 421 SO2CH3 3-pyridyl 2- (aminosulfonyl)phenyl 422 SO2CH3 3-pyridyl 2- (methylaminosulfonyl)phenyl 423 SO2CH3 3-pyridyl 1-pyrro1idinocarbony1 424 SO2CH 3 3 -pyridyl 2- (methylsulfonyl) phenyl 425 S0 2 CH 3 3-pyridyl 4-morpholino 426 S0 2 CH 3 3-pyridyl 2- ( 1 ' -CF3 - tetrazol-2 -yD phenyl 427 SO 2 CH 3 3-pyridyl 4-morpholinocarbonyl 428 SO 2 CH 3 3-pyridyl 2-methyl-l-imidazolyl 429 SO 2 CH 3 3-pyridyl 5-methyl-l-imidazolyl 430 S0 2 CH 3 3-pyridyl 2-methylsulfonyl-l-imidazolyl 431 S0 2 CH 3 2-pyrimidyl 2- (aminosulfonyl) phenyl 432 S0 2 CH 3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 433 SO 2 CH 3 2-pyrimidyl 1-pyrrolidinocarbonyl 434 S0 2 CH 3 2-pyrimidyl 2- (methylsulfonyl) phenyl 435 S0 2 CH 3 2-pyrimidyl 4-morpholino 436 S0 2 CH 3 2-pyrimidyl 2- (1' -CF3-tetrazol-2-yl)phenyl 437 S0 2 CH 3 2-pyrimidyl 4-morpho1inocarbony1 438 S0 2 CH 3 2-pyrimidyl 2-methyl-l-imidazolyl 439 S0CH 3 2-pyrimidyl 5-methyl-l-imidazolyl 440 SQ 2 CH 3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl 441 S0 2 CH 3 5-pyrimidyl 2- (aminosulfonyl) phenyl 442 S0CH 3 5-pyrimidyl 2- (methylaminosulfonyl)phenyl 443 S0 2 CH 3 5-pyrimidyl 1-pyrro1idinocarbony1 444 S0 2 CH 3 5-pyrimidyl 2- (methylsulfonyl ) phenyl 445 S0 2 CH 3 5-pyrimidyl 4-morpho1ino 446 S0 2 CH 3 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl 447 SO 2 CH 3 5-pyrimidyl 4-morpholinocarbonyl 448 S0 2 CH 3 5-pyrimidyl 2-methyl-1-imidazoly1 449 S0 2 CH 3 5-pyrimidyl 5-methyl-l-imidazolyl 450 S0 2 CH 3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl 451 S0 2 CH 3 2-Cl-phenyl 2- (aminosulfonyl) phenyl 452 S0 2 CH 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 453 SO 2 CH 3 2-Cl-phenyl 1-pyrrolidinocarbonyl 454 S0 2 CH 3 2-Cl-phenyl 2- (methylsulfonyl) phenyl 455 S0 2 CH 3 2-Cl-phenyl 4-morpholino 456 S0 2 CH 3 2-Cl-phenyl 2- (1' -CF3-tetrazol-2-yl)phenyl 457 SO 2 CH 3 2-Cl-phenyl 4-morpholinocarbonyl 458 SO 2 CH 3 2-Cl-phenyl 2-methy1-1-imidazolyl 459 SO 2 CH 3 2-Cl-phenyl 5-methyl-l-imidazolyl 460 SQ 2 CH 3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl 461 SO2CH3 2-F-phenyl 2- (aminosulfonyl) phenyl 462 S0 2 CH 3 2-F-phenyl 2- (methylaminosulfonyl) phenyl 463 S0 2 CH 3 2-F-phenyl 1-pyrro1idinocarbony1 464 S0 2 CH 3 2-F-phenyl 2- (methylsulfonyl)phenyl 465 S0 2 CH 3 2-F-phenyl 4-morpholino 466 SO 2 CH 3 2-F-phenyl 2- ( 1 ' -CF3 - tetrazol-2 -yD phenyl 467 SO 2 CH 3 2-F-phenyl 4-morpholinocarbonyl 468 SO 2 CH 3 2-F-phenyl 2-methyl-l-imidazolyl 469 SO 2 CH 3 2-F-phenyl 5-methyl-l-imidazolyl 470 SO 2 CH 3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl 471 S0 2 CH 3 2,6-diF-phenyl 2- (aminosulfonyl)phenyl 472 S0 2 CH 3 2,6-diF-phenyl 2- (methylaminosulfonyl)phenyl 473 S0 2 CH 3 2,6-diF-phenyl 1-pyrrolidinocarbonyl 474 SO2CH3 2,6-diF-phenyl 2- (methylsulfonyl) phenyl 475 SO2CH3 2,6-diF-phenyl 4-morpholino 476 SO2CH3 2,6-diF-phenyl 2- ( 1 ' -CF3 - tetrazol-2 -yD phenyl 477 SO2CH3 2,6-diF-phenyl 4-morpholinocarbonyl 478 SO2CH3 2,6-diF-phenyl 2-methyl-l-imidazolyl 479 SO2CH3 2,6-diF-phenyl 5-methyl-l-imidazolyl 480 SO2CH3 2,6-diF-phenyl 2-methylsulfonyl-l-imidazolyl 481 CHNH- phenyl 2- (aminosulfonyl) phenyl SO 2 CH 3 482 CH 2 NH- phenyl 2- (methylaminosulfonyl) phenyl SO 2 CH 3 483 CH 2 NH- phenyl 1-pyrrolidinocarbonyl SO 2 CH 3 484 CH 2 NH- phenyl 2- (methylsulfonyl)phenyl S0CH 3 485 CH 2 NH- phenyl 4-morpho1ino SO 2 CH 3 486 CH 2 NH- phenyl 2-(l' -CF3-tetrazol-2-yDphenyl SO 2 CH 3 487 CH 2 NH- phenyl 4-morpholinocarbonyl S0 2 CH 3 488 CH 2 NH- phenyl 2-methyl-l-imidazolyl SO 2 CH 3 489 CH 2 NH- phenyl 5-methyl-l-imidazolyl SO 2 CH 3 490 CH 2 NH- phenyl 2-methylsulfonyl-l-imidazolyl S0 2 CH 3 491 CH 2 NH- 2-pyridyl 2- (aminosulfonyl) phenyl SO 2 CH 3 492 CH 2 NH- 2-pyridyl 2- (methylaminosulfonyl)phenyl SO 2 CH 3 493 CH 2 NH- 2-pyridyl 1-pyrrolidinocarbonyl S0 2 CH 3 494 CH 2 NH- 2-pyridyl 2- (methylsulfonyl) phenyl SO2CH3 495 CH 2 NH- 2-pyridyl 4-morpholino SO 2 CH 3 496 CH 2 NH- 2-pyridyl 2- (1' -CF3-tetrazol-2-yl)phenyl SO 2 CH 3 497 CH 2 NH- 2-pyridyl 4-morpholinocarbonyl S0 2 CH 3 498 CH 2 NH- 2-pyridyl 2-methyl-l-imidazolyl S0 2 CH 3 499 CH 2 NH- 2-pyridyl 5-methyl-l-imidazolyl S0 2 CH 3 500 CH 2 NH- 2-pyridyl 2-methylsulfonyl-l-imidazolyl S0 2 CH 3 501 CH 2 NH- 3-pyridyl 2- (aminosulfonyl) phenyl SO 2 CH 3 502 CH 2 NH- 3-pyridyl 2- (methylaminosulfonyl) phenyl SO 2 CH 3 503 CH 2 NH- 3-pyridyl 1-pyrrolidinocarbonyl SO 2 CH 3 504 CH 2 NH- 3-pyridyl 2- (methylsulfonyl) phenyl SO 2 CH 3 505 CH 2 NH- 3-pyridyl 4-morpho1ino SO 2 CH 3 506 CH 2 NH- 3-pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl SO 2 CH 3 507 CH 2 NH- 3-pyridyl 4-morpholinocarbonyl SO 2 CH 3 508 CH 2 NH- 3-pyridyl 2-methyl-l-imidazolyl S0CH 3 509 CH 2 NH- 3-pyridyl 5-methyl-l-imidazolyl SO 2 CH 3 510 CH 2 NH- 3-pyridyl 2-methylsulfonyl-l-imidazolyl SO 2 CH 3 511 CHNH- 2-pyrimidyl 2- (aminosulfonyl)phenyl SO2CH3 512 CH 2 NH- 2-pyrimidyl 2- (methylaminosulfonyl) phenyl SO 2 CH 3 513 CH 2 NH- 2-pyrimidyl 1-pyrrolidinocarbonyl S0CH 3 514 CH 2 NH- 2-pyrimidyl 2- (methylsulfonyl) phenyl SO 2 CH 3 515 CHNH- 2-pyrimidyl 4-morpholino S0 2 CH 3 516 CH 2 NH- 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl SO 2 CH 3 517 CHNH- 2-pyrimidyl 4-morpholinocarbonyl SO 2 CH 3 518 CH 2 NH- 2-pyrimidyl 2-methyl-l-imidazolyl SO 2 CH 3 519 CH 2 NH- 2-pyrimidyl 5-methyl-l-imidazolyl SO2CH3 520 CH 2 NH- 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl SO 2 CH 3 521 CH 2 NH- 5-pyrimidyl 2- (aminosulfonyl)phenyl SO 2 CH 3 522 CH 2 NH- 5-pyrimidyl 2- (methylaminosulfonyl)phenyl S0 2 CH 3 523 CH 2 NH- 5-pyrimidyl 1-pyrrolidinocarbonyl S0 2 CH 3 524 CH 2 NH- 5-pyrimidyl 2- (methylsulfonyl)phenyl SO 2 CH 3 525 CH 2 NH- 5-pyrimidyl 4-morpho1ino S0CH 3 526 CH 2 NH- 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl S0 2 CH 3 527 CH 2 NH- 5-pyrimidyl 4-morpholinocarbonyl SO 2 CH 3 528 CH 2 NH- 5-pyrimidyl 2-methyl-l-imidazolyl SO 2 CH 3 529 CH 2 NH- 5-pyrimidyl 5-methyl-l-imidazolyl SO 2 CH 3 530 CH 2 NH- 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl SQ 2 CH 3 531 CH 2 NH- 2-Cl-phenyl 2- (aminosulfonyl)phenyl S0 2 CH 3 532 CH 2 NH- 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl S0 2 CH 3 533 CH 2 NH- 2-Cl-phenyl 1-pyrrolidinocarbonyl S0CH 3 534 CH 2 NH- 2-Cl-phenyl 2- (methylsulfonyl) phenyl S0 2 CH 3 535 CH 2 NH- 2-Cl-phenyl 4-morpholino SO 2 CH 3 536 CH 2 NH- 2-Cl-phenyl 2- (1' -CF3-tetrazol-2-yDphenyl SO 2 CH 3 537 CH 2 NH- 2-Cl-phenyl 4-morpholinocarbonyl S0 2 CH 3 538 CH 2 NH- 2-Cl-phenyl 2-methyl-l-imidazolyl S0 2 CH 3 539 CH 2 NH- 2-Cl-phenyl 5-methyl-l-imidazolyl SO 2 CH 3 540 CH 2 NH- 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl SO 2 CH 3 541 CH 2 NH- 2-F-phenyl 2- (aminosulfonyl) phenyl SO 2 CH 3 542 CH 2 NH- 2-F-phenyl 2- (methylaminosulfonyl)phenyl S0 2 CH 3 543 CH 2 NH- 2-F-phenyl 1-pyrrolidinocarbonyl S0 2 CH 3 544 CH 2 NH- 2-F-phenyl 2- (methylsulfonyl ) phenyl S0 2 CH 3 545 CH 2 NH- 2-F-phenyl 4-morpholino S0 2 CH 3 546 CH 2 NH- 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl SO 2 CH 3 547 CH 2 NH- 2-F-phenyl 4-morpholinocarbonyl S0 2 CH 3 548 CH 2 NH- 2-F-phenyl 2-methyl-l-imidazolyl S0 2 CH 3 549 CH 2 NH- 2-F-phenyl 5-methyl-l-imidazolyl S0 2 CH 3 550 CHNH- 2-F-phenyl 2-methylsulfonyl-l-imidazolyl S0CH 551 CHNH- 2 , 6-diF-phenyl 2- (aminosulfonyl) phenyl S0CH 3 552 CH 2 NH- 2, , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl SO 2 CH 3 553 CH 2 NH- 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl SO 2 CH 3 554 CH 2 NH- 2, , 6-diF-phenyl 2- (methylsulfonyl) phenyl S0 2 CH 3 555 CH 2 NH- 2, , 6-diF-phenyl 4-morpholino SO 2 CH 3 556 CH 2 NH- 2, , 6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl SO 2 CH 3 557 CH 2 NH- 2, , 6-diF-phenyl 4-morpholinocarbonyl S0 2 CH 3 558 CH 2 NH- 2 , , 6-diF-phenyl 2-methyl-l-imidazolyl S0 2 CH 3 559 CHNH- 2, .6-diF-phenyl 5-methyl-l-imidazolyl S0 2 CH 3 560 CH 2 NH- 2, , 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl S0CH 3 561 Cl phenyl 2- (aminosulfonyl) phenyl 562 Cl phenyl 2- (methylaminosulfonyl)phenyl 563 Cl phenyl 1-pyrr01idinocarbony1 564 Cl phenyl 2- (methylsulfonyl)phenyl 565 Cl phenyl 4-morpho1ino 566 Cl phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl 567 Cl phenyl 4-morpholinocarbonyl 568 Cl phenyl 2-methyl-l-imidazolyl 569 Cl phenyl 5-methyl-l-imidazolyl 570 Cl phenyl 2-methylsulfonyl-l-imidazolyl 571 Cl 2-pyridyl 2- (aminosulfonyl) phenyl 572 Cl 2-pyridyl 2- (methylaminosulfonyl)phenyl 573 Cl 2-pyridyl 1-pyrrolidinocarbonyl 574 Cl 2-pyridyl 2- (methylsulfonyl) henyl 575 Cl 2-pyridyl 4-morpholino 576 Cl 2-pyridyl 2- (1 ' -CF3 -tetrazol-2-yl)phenyl 577 Cl 2-pyridyl 4-morpholinocarbonyl 578 Cl 2-pyridyl 2-methyl-l-imidazolyl 579 Cl 2-pyridyl 5-methyl-l-imidazolyl 580 Cl 2-pyridyl 2-methylsulfonyl-l-imidazolyl 581 Cl 3-pyridyl 2- (aminosulfonyl) phenyl 582 Cl 3-pyridyl 2- (methylaminosulfonyl)phenyl 583 Cl 3-pyridyl 1-pyrro1idinocarbony1 584 Cl 3-pyridyl 2- (methylsulfonyl) phenyl 585 Cl 3-pyridyl 4-morpho1ino 586 Cl 3-pyridyl 2- (1' -CF3-tetrazol-2-yDphenyl 587 Cl 3-pyridyl 4-morpholinocarbonyl 588 Cl 3-pyridyl 2-methyl-l-imidazolyl 589 Cl 3-pyridyl 5-methyl-l-imidazolyl 590 Cl 3-pyridyl 2-methylsulfonyl-l-imidazolyl 591 Cl 2-pyrimidyl 2- (aminosulfonyl)phenyl 592 Cl 2-pyrimidyl 2- (methylaminosulfonyl)phenyl 593 Cl 2-pyrimidyl 1-pyrrolidinocarbonyl 594 Cl 2-pyrimidyl 2- (methylsulfonyl)phenyl 595 Cl 2-pyrimidyl 4-morpho1ino 596 Cl 2-pyrimidyl 2- (1' -CF3-tetrazol-2-yl) phenyl 597 Cl 2-pyrimidyl 4-morpholinocarbonyl 598 Cl 2-pyrimidyl 2-methyl-l-imidazolyl 599 Cl 2-pyrimidyl 5-methyl-l-imidazolyl 600 Cl 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl 601 Cl 5-pyrimidyl 2- (aminosulfonyl) phenyl 602 Cl 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 603 Cl 5-pyrimidyl 1-pyrro1idinocarbony1 604 Cl 5-pyrimidyl 2- (methylsulfonyl) phenyl 605 Cl 5-pyrimidyl 4-morpholino 606 Cl 5-pyrimidyl 2- (l'-CF3-tetrazol-2-yDphenyl 607 Cl 5-pyrimidyl 4-morpholinocarbonyl 608 Cl 5-pyrimidyl 2-methyl-l-imidazolyl 609 Cl 5-pyrimidyl 5-methyl-l-imidazolyl 610 Cl 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl 611 Cl 2-Cl-phenyl 2- (aminosulfonyl) phenyl 612 Cl 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 613 Cl 2-Cl-phenyl 1-pyrrolidinocarbonyl 614 Cl 2-Cl-phenyl 2- (methylsulfonyl) phenyl 615 Cl 2-Cl-phenyl 4-morpholino 616 Cl 2-Cl-phenyl 2- (1 '-CF3-tetrazol-2-yD henyl 617 Cl 2-Cl-phenyl 4-morpholinocarbonyl 618 Cl 2-Cl-phenyl 2-methyl-l-imidazolyl 619 Cl 2-Cl-phenyl 5-methyl-l-imidazolyl 620 Cl 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl 621 Cl 2-F-phenyl 2- (aminosulfonyl) phenyl 622 Cl 2-F-phenyl 2- (methylaminosulfonyl)phenyl 623 Cl 2-F-phenyl 1-pyrrolidinocarbonyl 624 Cl 2-F-phenyl 2- (methylsulfonyl) phenyl 625 Cl 2-F-phenyl 4-morpholino 626 Cl 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl 627 Cl 2-F-phenyl 4-morpho1inocarbony1 628 Cl 2-F-phenyl 2-methyl-l-imidazolyl 629 Cl 2-F-phenyl 5-methyl-l-imidazolyl 630 Cl 2-F-phenyl 2-methylsulfonyl-l-imidazolyl 631 Cl 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl 632 Cl 2, 6-diF-phenyl 2- (methylaminosulfonyl)phenyl 633 Cl 2,6-diF-phenyl 1-pyrrolidinocarbonyl 634 Cl 2, 6-diF-phenyl 2- (methylsulfonyl) phenyl 635 Cl 2,6-diF-phenyl 4-morpho1ino 636 Cl 2, 6-diF-phenyl 2- ( 1 ' -CF3 -tetrazol -2 -yD phenyl 637 Cl 2, 6-diF-phenyl 4-morpholinocarbonyl 638 Cl 2,6-diF-phenyl 2-methyl-l-imidazolyl 639 Cl 2,6-diF-phenyl 5-methyl-l-imidazolyl 640 Cl 2,6-diF-phenyl 2-methylsulfonyl-l-imidazolyl 641 F phenyl 2- (aminosulfonyl) phenyl 642 F phenyl 2- (methylaminosulfonyl) phenyl 643 F phenyl 1-pyrrolidinocarbonyl 644 F phenyl 2- (methylsulfonyl) phenyl 645 F phenyl 4-morpho1ino 646 F phenyl 2- (1 ' -CF3-tetrazol-2-yDphenyl 647 F phenyl 4-morpholinocarbonyl 648 F phenyl 2-methyl-l-imidazolyl 649 F phenyl 5-methyl-l-imidazolyl 650 F phenyl 2-methylsulfonyl-l-imidazolyl 651 F 2-pyridyl 2- (aminosulfonyl) phenyl 652 F 2-pyridyl 2- (methylaminosulfonyl) phenyl 653 F 2-pyridyl 1-pyrrolidinocarbonyl 654 F 2-pyridyl 2- (methylsulfonyl) phenyl 655 F 2-pyridyl 4-morpho1ino 656 F 2-pyridyl 2- (1' -CF3-tetrazol-2-yl)phenyl 657 F 2-pyridyl 4-morpholinocarbonyl 658 F 2-pyridyl 2-methyl-l-imidazolyl 659 F 2-pyridyl 5-methyl-l-imidazolyl 660 F 2-pyridyl 2-methylsulfonyl-l-imidazolyl 661 F 3-pyridyl 2- (aminosulfonyl)phenyl 662 F 3-pyridyl 2- (methylaminosulfonyl)phenyl 663 F 3-pyridyl 1-pyrrolidinocarbonyl 664 F 3-pyridyl 2- (methylsulfonyl)phenyl 665 F 3-pyridyl 4-morpholino 666 F 3-pyridyl 2- (1' -CF3-tetrazol-2-yl)phenyl 667 F 3-pyridyl 4-morpholinocarbonyl 668 F 3-pyridyl 2-methyl-l-imidazolyl 669 F 3-pyridyl 5-methyl-l-imidazolyl 670 F 3-pyridyl 2-methylsulfonyl-l-imidazolyl 671 F 2-pyrimidyl 2- (aminosulfonyl)phenyl 672 F 2-pyrimidyl 2- (methylaminosulfonyl)phenyl 673 F 2-pyrimidyl 1-pyrro1idinocarbony1 674 F 2-pyrimidyl 2- (methylsulfonyl)phenyl 675 F 2-pyrimidyl 4-morpholino 676 F 2-pyrimidyl 2- (1' -CF3-tetrazol-2-yl)phenyl 677 F 2-pyrimidyl 4-morpho1inocarbony1 678 F 2-pyrimidyl 2-methyl-1-imidazolyl 679 F 2-pyrimidyl 5-methyl-l-imidazolyl 680 F 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl 681 F 5-pyrimidyl 2- (aminosulfonyl) phenyl 682 F 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 683 F 5-pyrimidyl 1-pyrrolidinocarbonyl 684 F 5-pyrimidyl 2- (methylsulfonyl) phenyl 685 F 5-pyrimidyl 4-morpholino 686 F 5-pyrimidyl 2- (1' -CF3-tetrazol-2-yl) phenyl 687 F 5-pyrimidyl 4-morpholinocarbonyl 688 F 5-pyrimidyl 2-methyl-l-imidazolyl 689 F 5-pyrimidyl 5-methyl-l-imidazolyl 690 F 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl 691 F 2-Cl-phenyl 2- (aminosulfonyl) phenyl 692 F 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 693 F 2-Cl-phenyl 1-pyrrolidinocarbonyl 694 F 2-Cl-phenyl 2- (methylsulfonyl) phenyl 695 F 2-Cl-phenyl 4-morpholino 696 F 2-Cl-phenyl 2- (l'-CF3-tetrazol-2-yl) henyl 697 F 2-Cl-phenyl 4-morpho1inocarbony1 698 F 2-Cl-phenyl 2-methyl-l-imidazolyl 699 F 2-Cl-phenyl 5-methyl-l-imidazolyl 700 F 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl 701 F 2-F-phenyl 2- (aminosulfonyl) phenyl 702 F 2-F-phenyl 2- (methylaminosulfonyl)phenyl 703 F 2-F-phenyl 1-pyrro1idinocarbony1 704 F 2-F-phenyl 2- (methylsulfonyl) phenyl 705 F 2-F-phenyl 4-morpho1ino 706 F 2-F-phenyl 2- ( D -CF3 -tetrazol-2 -yD phenyl 707 F 2-F-phenyl 4-morpholinocarbonyl 708 F 2-F-phenyl 2-methyl-l-imidazolyl 709 F 2-F-phenyl 5-methy1-1-imidazoly1 710 F 2-F-phenyl 2-methylsulfonyl-l-imidazolyl 711 2, 6-diF-phenyl 2- (aminosulfonyl)phenyl 712 F 2, 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 713 F 2, 6-diF-phenyl 1-pyrrolidinocarbonyl 714 F 2 , 6-diF-phenyl 2- (methylsulfonyl) phenyl 715 F 2, 6-diF-phenyl 4-morpholino 716 F 2, 6-diF-phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 717 F 2, 6-diF-phenyl 4-morpholinocarbonyl 718 F 2 , 6-diF-phenyl 2-methyl-l-imidazolyl 719 F 2, 6-diF-phenyl 5-methyl-l-imidazolyl 720 F 2, 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl 721 C0 2 CH 3 phenyl 2- (aminosulfonyl) phenyl 722 CO2CH3 phenyl 2- (methylaminosulfonyl) phenyl 723 CO2CH3 phenyl 1-pyrrolidinocarbonyl 724 C0 2 CH 3 phenyl 2- (methylsulfonyl)phenyl 725 C0 2 CH 3 phenyl 4-morpholino 726 C0 2 CH 3 phenyl 2- (1' -CF3-tetrazol-2-yl)phenyl 727 C0 2 CH 3 phenyl 4-morpholinocarbonyl 728 C0 2 CH 3 phenyl 2-methyl-l-imidazolyl 729 C0 2 CH 3 phenyl 5-methyl-l-imidazolyl 730 C0 2 CH phenyl 2-methylsulfonyl-l-imidazolyl 731 C0 2 CH 3 2-pyridyl 2- (aminosulfonyl) phenyl 732 C0 2 CH 3 2-pyridyl 2- (methylaminosulfonyl) phenyl 733 CO2CH 3 2-pyridyl 1-pyrro1idinocarbony1 734 CO2CH3 2-pyridyl 2- (methylsulfonyl) phenyl 735 C0 2 CH 3 2-pyridyl 4-morpho1ino 736 C0 CH 3 2-pyridyl 2- (l'-CF3-tetrazol-2-yDphenyl 737 C0 2 CH 3 2-pyridyl 4-morpholinocarbonyl 738 C0 2 CH 3 2-pyridyl 2-methyl-l-imidazolyl 739 C0 2 CH 3 2-pyridyl 5-methyl-l-imidazolyl 740 C0 2 CH 3 2-pyridyl 2-methylsulfonyl-l-imidazolyl 741 C0 2 CH 3-pyridyl 2- (aminosulfonyl) phenyl 742 CO2CH 3 3-pyridyl 2- (methylaminosulfonyl) phenyl 743 CO2CH 3 3-pyridyl 1-pyrro1idinocarbony1 744 CO2CH3 3 -pyridyl 2- (methylsulfonyl) phenyl 745 CO2CH3 3 -pyridyl 4-morpholino 746 C0 2 CH 3 3-pyridyl 2- ( 1 ' -CF3 -tetrazol-2 -yD phenyl 747 C0 2 CH 3 3-pyridyl 4-morpholinocarbonyl 748 C0CH 3 3-pyridyl 2-methyl-l-imidazolyl 749 C0CH 3 3-pyridyl 5-methyl-l-imidazolyl 750 CO2CH3 3-pyridyl 2-methylsulfonyl-l-imidazolyl 751 C0 2 CH 3 2-pyrimidyl 2- (aminosulfonyl) phenyl 752 C0 2 CH 3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 753 CO 2 CH 3 2-pyrimidyl 1-pyrrolidinocarbonyl 754 CO 2 CH 3 2-pyrimidyl 2- (methylsulfonyl)phenyl 755 CO 2 CH 3 2-pyrimidyl 4-morpholino 756 CO 2 CH 3 2-pyrimidyl 2- (l'-CF3-tetrazol-2-yl) phenyl 757 CO 2 CH 3 2-pyrimidyl 4-morpholinocarbonyl 758 CO 2 CH 3 2-pyrimidyl 2-methyl-l-imidazolyl 759 C0 2 CH 3 2-pyrimidyl 5-methyl-l-imidazolyl 760 CO 2 CH 3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl 761 C0 2 CH 3 5-pyrimidyl 2- (aminosulfonyl) phenyl 762 CO2CH3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 763 CO2CH3 5-pyrimidyl 1-pyrrolidinocarbonyl 764 CO2CH3 5-pyrimidyl 2- (methylsulfonyl) phenyl 765 C0 CH 3 5-pyrimidyl 4-morpho1ino 766 C0 2 CH 3 5-pyrimidyl 2- (l'-CF3-tetrazol-2-yl) phenyl 767 CO2CH3 5-pyrimidyl 4-morpholinocarbonyl 768 CO2CH3 5-pyrimidyl 2-methyl-l-imidazolyl 769 CO2CH3 5-pyrimidyl 5-methyl-l-imidazolyl 770 CO2CH3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl 771 CO2CH3 2-Cl-phenyl 2- (aminosulfonyl) phenyl 772 C0 2 CH 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 773 C0 2 CH 3 2-Cl-phenyl 1-pyrrolidinocarbonyl 774 CO2CH3 2-Cl-phenyl 2- (methylsulfonyl) phenyl 775 CO2CH3 2-Cl-phenyl 4-morpholino 776 CO2CH3 2-Cl-phenyl 2- (l'-CF3-tetrazol-2-yDphenyl 777 CO2CH3 2-Cl-phenyl 4-morpholinocarbonyl 778 CO2CH3 2-Cl-phenyl 2-methyl-l-imidazolyl 779 C0 2 CH 3 2-Cl-phenyl 5-methyl-l-imidazolyl 780 CQ 2 CH 3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl 781 CO2CH3 2-F-phenyl 2- (aminosulfonyl) phenyl 782 CO2CH3 2-F-phenyl 2- (methylaminosulfonyl)phenyl 783 C0 2 CH 3 2-F-phenyl 1-pyrro1idinocarbony1 784 CO2CH3 2-F-phenyl 2- (methylsulfonyl)phenyl 785 CO2CH3 2-F-phenyl 4-morpholino 786 C0 2 CH 3 2 -F-phenyl 2 - ( l ' -CF3 - tetrazol-2 -yD phenyl 787 C0 2 CH 3 2 -F-phenyl 4-morpholinocarbonyl 788 CO2CH3 2 -F-phenyl 2-methyl-l-imidazolyl 789 CO2CH3 2 -F-phenyl 5-methyl-l-imidazolyl 790 CO2CH 3 2 -F-phenyl 2-methylsulfonyl-l-imidazolyl 791 CO2CH 3 2, , 6-diF-phenyl 2- (aminosulfonyl) phenyl 792 CO2CH 3 2, , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 793 CO2CH 3 2, , 6-diF-phenyl 1-pyrrolidinocarbonyl 794 CO2CH3 2, .6-diF-phenyl 2- (methylsulfonyl)phenyl 795 CO2CH3 2, .6-diF-phenyl 4-morpholino 796 CO2CH3 2, .6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 797 C0CH 3 2, .6-diF-phenyl 4-morpholinocarbonyl 798 C0 2 CH 3 2, 6-diF-phenyl 2-methyl-l-imidazolyl 799 C0 2 CH 3 2, 6-diF-phenyl 5-methyl-l-imidazolyl 800 C0 2 CH 2, 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl 801 CH 2 OCH 3 phenyl 2- (aminosulfonyl) phenyl 802 CH 2 OCH 3 phenyl 2- (methylaminosulfonyl) phenyl 803 CH 2 OCH 3 phenyl 1-pyrrolidinocarbonyl 804 CH 2 OCH 3 phenyl 2- (methylsulfonyl) phenyl 805 CH 2 OCH 3 phenyl 4-morpholino 806 CH2OCH 3 phenyl 2- (1' -CF3-tetrazol-2-yDphenyl 807 CH2OCH 3 phenyl 4-morpho1inocarbony1 808 CH2OCH3 phenyl 2-methyl-l-imidazolyl 809 CH2OCH 3 phenyl 5-methyl-l-imidazolyl 810 CH2OCH3 phenyl 2-methylsulfonyl-l-imidazolyl 811 CH 2 OCH 3 2-pyridyl 2- (aminosulfonyl) phenyl 812 CH2OCH 3 2-pyridyl 2- (methylaminosulfonyl) phenyl 813 CH2OCH3 2-pyridyl 1-pyrrolidinocarbonyl 814 CH2OCH3 2-pyridyl 2- (methylsulfonyl) phenyl 815 CH 2 OCH 3 2-pyridyl 4-morpho1ino 816 CH2OCH3 2-pyridyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl 817 CH 2 OCH 3 2-pyridyl 4-morpho1inocarbony1 818 CH2OCH3 2-pyridyl 2-methyl-l-imidazolyl 819 CH 2 OCH 3 2-pyridyl 5-methyl-l-imidazolyl 820 CH 2 OCH 3 2-pyridyl 2-methylsulfonyl-l-imidazolyl 821 CH2OCH3 3-pyridyl 2- (aminosulfonyl)phenyl 822 CH 2 OCH 3 3-pyridyl 2- (methylaminosulfonyl) phenyl 823 CH 2 OCH 3 3-pyridyl 1-pyrrolidinocarbonyl 824 CH 2 OCH 3 3-pyridyl 2- (methylsulfonyl) phenyl 825 CH 2 OCH 3 3-pyridyl 4-morpholino 826 CH 2 OCH 3 3-pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl 827 CH 2 OCH 3 3-pyridyl 4-morpholinocarbonyl 828 CH 2 OCH 3 3-pyridyl 2-methyl-l-imidazolyl 829 CH 2 OCH 3 3-pyridyl 5-methyl-l-imidazolyl 830 CH 2 OCH 3 3-pyridyl 2-methylsulfonyl-l-imidazolyl 831 CH 2 OCH 3 2-pyrimidyl 2- (aminosulfonyl) phenyl 832 CH 2 OCH 3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 833 CH 2 OCH 3 2-pyrimidyl 1-pyrrolidinocarbonyl 834 CH 2 OCH 3 2-pyrimidyl 2- (methylsulfonyl) phenyl 835 CH 2 OCH 3 2-pyrimidyl 4-morpho1ino 836 CH 2 OCH 3 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 837 CH 2 OCH 3 2-pyrimidyl 4-morpholinocarbonyl 838 CH 2 OCH 3 2-pyrimidyl 2-methyl-l-imidazolyl 839 CH 2 OCH 3 2-pyrimidyl 5-methyl-l-imidazolyl 840 CHOCH 3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl 841 CH 2 OCH 3 5-pyrimidyl 2- (aminosulfonyl)phenyl 842 CH 2 OCH 3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 843 CH 2 OCH 3 5-pyrimidyl 1-pyrrolidinocarbonyl 844 CH 2 OCH 3 5-pyrimidyl 2- (methylsulfonyl) phenyl 845 CHOCH 3 5-pyrimidyl 4-morpho1ino 846 CH 2 OCH 3 5-pyrimidyl 2- (1' -CF3-tetrazol-2-yl) phenyl 847 CH 2 OCH 3 5-pyrimidyl 4-morpholinocarbonyl 848 CH 2 OCH 3 5-pyrimidyl 2-methyl-l-imidazolyl 849 CH 2 OCH 3 5-pyrimidyl 5-methyl-l-imidazolyl 850 CH 2 OCH 3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl 851 CH 2 OCH 3 2-Cl-phenyl 2- (aminosulfonyl)phenyl 852 CH 2 OCH 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 853 CH 2 OCH 3 2-Cl-phenyl 1-pyrrolidinocarbonyl 854 CHOCH 3 2-Cl-phenyl 2- (methylsulfonyl) henyl 855 CH 2 OCH 3 2-Cl-phenyl 4-morpho1ino 856 CH 2 OCH 3 2-Cl-phenyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl 857 CH 2 OCH 3 2-Cl-phenyl 4-morpholinocarbonyl 858 CH 2 OCH 3 2-Cl-phenyl 2-methyl-l-imidazolyl 859 CH 2 OCH 3 2-Cl-phenyl 5-methyl-l-imidazolyl 860 CH2OCH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl 861 CH 2 OCH 3 2-F-phenyl 2- (aminosulfonyl)phenyl 862 CH 2 OCH 3 2-F-phenyl 2- (methylaminosulfonyl) phenyl 863 CH 2 OCH 3 2-F-phenyl 1-pyrrolidinocarbonyl 864 CH 2 OCH 3 2-F-phenyl 2- (methylsulfonyl) phenyl 865 CH 2 OCH 3 2-F-phenyl 4-morpholino 866 CH 2 OCH 3 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 867 CHOCH 3 2-F-phenyl 4-morpho1inocarbony1 868 CH 2 OCH 3 2-F-phenyl 2-methyl-l-imidazolyl 869 CH 2 OCH 2-F-phenyl 5-methyl-l-imidazolyl 870 CH2OCH3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl 871 CH 2 OCH 3 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl 872 CH2OCH3 2, 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 873 CH 2 OCH 3 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl 874 CH 2 OCH 3 2, 6-diF-phenyl 2- (methylsulfonyl ) phenyl 875 CH 2 OCH 3 2, 6-diF-phenyl 4-morpholino 876 CH 2 OCH 3 2, 6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl 877 CH 2 OCH 3 2, 6-diF-phenyl 4-morpholinocarbonyl 878 CH 2 OCH 3 2, 6-diF-phenyl 2-methyl-l-imidazolyl 879 CH 2 OCH 3 2, 6-diF-phenyl 5-methyl-l-imidazolyl 880 CH 2 OCH 3 2, 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl 881 CONH2 phenyl 2- (aminosulfonyl) phenyl 882 CONH 2 phenyl 2- (methylaminosulfonyl) phenyl 883 CONH 2 phenyl 1-pyrrolidinocarbonyl 884 CONH 2 phenyl 2- (methylsulfonyl) phenyl 885 CONH 2 phenyl 4-morpholino 886 CONH 2 phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 887 CONH 2 phenyl 4-morpholinocarbonyl 888 CONH 2 phenyl 2-methyl-l-imidazolyl 889 CONH 2 phenyl 5-methyl-l-imidazolyl 890 CONH 2 phenyl 2-methylsulfonyl-l-imidazolyl 891 CONH2 2-pyridyl 2- (aminosulfonyl)phenyl 892 C0NH 2 2-pyridyl 2- (methylaminosulfonyl) phenyl 893 C0NH 2 2-pyridyl 1-pyrrolidinocarbonyl 894 CONH 2 2-pyridyl 2- (methylsulfonyl)phenyl 895 CONH 2 2-pyridyl 4-morpho1ino 896 CONH2 2-pyridyl 2-(l'-CF3-tetrazol-2-yl)phenyl 897 CONH 2-pyridyl 4-morpholinocarbonyl 898 CONH 2 2-pyridyl 2-methyl-l-imidazolyl 899 CONH 2 2-pyridyl 5-methyl-l-imidazolyl 900 CONH 2 2-pyridyl 2-methylsulfonyl-l-imidazolyl 901 CONH 2 3-pyridyl 2- (aminosulfonyl)phenyl 902 CONH 2 3-pyridyl 2- (methylaminosulfonyl)phenyl 903 CONH 2 3-pyridyl 1-pyrrolidinocarbonyl 904 CONH2 3-pyridyl 2- (methylsulfonyl) phenyl 905 CONH 2 3-pyridyl 4-morpholino 906 CONH 2 3-pyridyl 2-(l' -CF3-tetrazol-2-yl) henyl 907 CONH 2 3-pyridyl 4-morpho1inocarbony1 908 CONH 2 3-pyridyl 2-methyl-l-imidazolyl 909 CONH2 3-pyridyl 5-methyl-l-imidazolyl 910 CONH2 3-pyridyl 2-methylsulfonyl-l-imidazolyl 911 CONH 2 2-pyrimidyl 2- (aminosulfonyl)phenyl 912 CONH 2 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 913 CONH 2 2-pyrimidyl 1-pyrro1idinocarbony1 914 CONH 2 2-pyrimidyl 2- (methylsulfonyl) phenyl 915 CONH2 2-pyrimidyl 4-morpho1ino 916 CONH2 2-pyrimidyl 2- (l'-CF3-tetrazol-2-yDphenyl 917 CONH 2 2-pyrimidyl 4-morpholinocarbonyl 918 CONH 2 2-pyrimidyl 2-methyl-l-imidazolyl 919 CONH 2 2-pyrimidyl 5-methyl-l-imidazolyl 920 CONH 2 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl 921 CONH 2 5-pyrimidyl 2- (aminosulfonyl) phenyl 922 CONH 2 5-pyrimidyl 2- (methylaminosulfonyl)phenyl 923 CONH 2 5-pyrimidyl 1-pyrrolidinocarbonyl 924 CONH 2 5-pyrimidyl 2- (methylsulfonyl) phenyl 925 CONH 2 5-pyrimidyl 4-morpholino 926 CONH 2 5-pyrimidyl 2-(l'-CF3-tetrazol-2-yl)phenyl 927 CONH 2 5-pyrimidyl 4-morpho1inocarbony1 928 CONH 2 5-pyrimidyl 2-methyl-l-imidazolyl 929 CONH 2 5-pyrimidyl 5-methyl-l-imidazolyl 930 CONH 2 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl 931 CONH 2 2-Cl-phenyl 2- (aminosulfonyl) phenyl 932 CONH2 2-Cl-phenyl 2- (methylaminosulfonyl)phenyl 933 CONH 2 2-Cl-phenyl 1-py ro1idinocarbony1 934 CONH 2 2-Cl-phenyl 2 - (methylsulfonyl ) phenyl 935 CONH 2 2-Cl-phenyl 4 -morpho 1 ino 936 CONH 2 2-Cl-phenyl 2- (1' -CF3-tetrazol-2-yDphenyl 937 CONH 2 2-Cl-phenyl 4-morpholinocarbonyl 938 CONH 2 2-Cl-phenyl 2-methyl-l-imidazolyl 939 CONH 2 2-Cl-phenyl 5-methyl-l-imidazolyl 940 CONH 2 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl 941 CONH 2 2-F-phenyl 2- (aminosulfonyl)phenyl 942 CONH 2 2-F-phenyl 2- (methylaminosulfonyl)phenyl 943 C0NH 2 2-F-phenyl 1-pyrrolidinocarbonyl 944 CONH 2 2-F-phenyl 2- (methylsulfonyl) phenyl 945 CONH 2 2-F-phenyl 4-morpho1ino 946 CONH 2 2-F-phenyl 2-(l' -CF3-tetrazol-2-yDphenyl 947 CONH2 2-F-phenyl 4-morpho1inocarbony1 948 CONH 2 2-F-phenyl 2-methyl-l-imidazolyl 949 CONH2 2-F-phenyl 5-methyl-l-imidazolyl 950 CONH 2-F-phenyl 2-methylsulfonyl-l-imidazolyl 951 CONH 2 2, , 6-diF-phenyl 2- (aminosulfonyl)phenyl 952 CONH 2 2, , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 953 CONH 2 2, , 6-diF-phenyl 1-pyrrolidinocarbonyl 954 CONH 2 2, , 6-diF-phenyl 2- (methylsulfonyl) phenyl 955 CONH 2 2, , 6-diF-phenyl 4-morpholino 956 CONH 2 2, , 6-diF-phenyl 2- ( D -CF3 - tetrazol-2 -yD phenyl 957 CONH 2 2, , 6-diF-phenyl 4-morpholinocarbonyl 958 CONH2 2, .6-diF-phenyl 2-methyl-l-imidazolyl 959 CONH 2 2, 6-diF-phenyl 5-methyl-l-imidazolyl 960 CONH 2 2, 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl Table 2 i J w aa ee gg hh qq rr ss Ex # A B 1 phenyl 2- (aminosulfonyl) phenyl 2 phenyl 2- (methylaminosulfonyl)phenyl 3 phenyl 1-pyrrolidinocarbonyl 4 phenyl 2- (methylsulfonyl) phenyl 5 phenyl 4-morpho1ino 6 phenyl 2- ( l ' -CF3 -tetrazol-2 -yD phenyl 7 phenyl 4-morpho1inocarbony1 8 phenyl 2-methyl-l-imidazolyl 9 phenyl 5-methyl-l-imidazolyl 10 phenyl 2-methylsulfonyl-l-imidazolyl 11 2-pyridyl 2- (aminosulfonyl) phenyl 12 2-pyridyl 2- (methylaminosulfonyl)phenyl 13 2-pyridyl 1-pyrro1idinocarbony1 14 2-pyridyl 2- (methylsulfonyl) phenyl 15 2-pyridyl 4-morpho1ino 16 2-pyridyl 2- (1' -CF3-tetrazol-2-yl)phenyl 17 2-pyridyl 4-morpholinocarbony1 2-pyridyl 2-methyl-l-imidazolyl 2-pyridyl 5-methyl-l-imidazolyl 2-pyridyl 2-methylsulfonyl-l-imidazolyl 3-pyridyl 2- (aminosulfonyl) phenyl 3-pyridyl 2- (methylaminosulfonyl) phenyl 3-pyridyl 1-pyrro1idinocarbony1 3-pyridyl 2- (methylsulfonyl) phenyl 3-pyridyl 4-morpholino 3-pyridyl 2- (l'-CF3-tetrazol-2-yDphenyl 3-pyridyl 4-morpho1inocarbony1 3-pyridyl 2-methyl-l-imidazolyl 3-pyridyl 5-methyl-l-imidazolyl 3-pyridyl 2-methylsulfonyl-1-imidazolyl 2-pyrimidyl 2- (aminosulfonyl)phenyl 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 2-pyrimidyl 1-pyrrolidinocarbonyl 2-pyrimidyl 2- (methylsulfonyl) phenyl 2-pyrimidyl 4-morpholino 2-pyrimidyl 2- (1' -CF3-tetrazol-2-yDphenyl 2-pyrimidyl 4-morpholinocarbonyl 2-pyrimidyl 2-methyl-l-imidazolyl 2-pyrimidyl 5-methyl-l-imidazolyl 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl 5-pyrimidyl 2- (aminosulfonyl) phenyl 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 5-pyrimidyl 1-pyrrolidinocarbonyl 5-pyrimidyl 2- (methylsulfonyl) phenyl 5-pyrimidyl 4-morpho1ino 5-pyrimidyl 2- (1' -CF3-tetrazol-2-yl)phenyl 5-pyrimidyl 4-morpholinocarbonyl 5-pyrimidyl 2-methyl-l-imidazolyl 5-pyrimidyl 5-methyl-l-imidazolyl 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl 2-Cl-phenyl 2- (aminosulfonyl) phenyl 2-Cl-phenyl 2- (methylaminosulfonyl)phenyl 2-Cl-phenyl 1-pyrrolidinocarbonyl 2-Cl-phenyl 2- (methylsulfonyl) phenyl 55 2-Cl-phenyl 4-morpholino 56 2-Cl-phenyl 2- (l'-CF3-tetrazol-2-yDphenyl 57 2-Cl-phenyl 4-morpholinocarbonyl 58 2-Cl-phenyl 2-methyl-l-imidazolyl 59 2-Cl-phenyl 5-methyl-l-imidazolyl 60 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl 61 2-F-phenyl 2- (aminosulfonyl) phenyl 62 2-F-phenyl 2- (methylaminosulfonyl)phenyl 63 2-F-phenyl 1-pyrro1idinocarbony1 64 2-F-phenyl 2- (methylsulfonyl) phenyl 65 2-F-phenyl 4-morpholino 66 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yDphenyl 67 2-F-phenyl 4-morpholinocarbonyl 68 2-F-phenyl 2-methyl-l-imidazolyl 69 2-F-phenyl 5-methyl-l-imidazolyl 70 2-F-phenyl 2-methylsulfonyl-l-imidazolyl 71 2,6-diF-phenyl 2- (aminosulfonyl) phenyl 72 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 73 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl 74 2,6-diF-phenyl 2- (methylsulfonyl) phenyl 75 2,6-diF-phenyl 4-morpholino 76 2,6-diF-phenyl 2-(l' -CF3-tetrazol-2-yl) phenyl 77 2,6-diF-phenyl 4-morpholinocarbonyl 78 2,6-diF-phenyl 2-methyl-l-imidazolyl 79 2,6-diF-phenyl 5-methyl-l-imidazolyl 80 2,6-diF-phenyl 2-methylsulfonyl-l-imidazolyl Utility The compounds of this invention are useful as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals. The term "thromboembolic disorders" as used herein includes arterial or venous cardiovascular or cerebrovascular thromboembolic disorders, including, for example, unstable angina, first or recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary and cerebral arterial thrombosis, cerebral embolism, kidney embolisms, and pulmonary embolisms. The anticoagulant effect of compounds of the present invention is believed to be due to inhibition of factor Xa or thrombin. The effectiveness of compounds of the present invention as inhibitors of factor Xa was determined using purified human factor Xa and synthetic substrate. The rate of factor Xa hydrolysis of chromogenic substrate S2222 (Kabi Pharmacia, Franklin, OH) was measured both in the absence and presence of compounds of the present invention. Hydrolysis of the substrate resulted in the release of pNA, which was monitored spectrophotometrically by measuring the increase in absorbance at 405 nM. A decrease in the rate of absorbance change at 405 nm in the presence of inhibitor is indicative of enzyme inhibition. The results of this assay are expressed as inhibitory constant, Ki . Factor Xa determinations were made in 0.10 M sodium phosphate buffer, pH 7.5, containing 0.20 M NaCI, and 0.5 % PEG 8000. The Michaelis constant, K m , for substrate hydrolysis was determined at 25°C using the method of Lineweaver and Burk. Values of Ki were determined by allowing 0.2-0.5 nM human factor Xa (Enzyme Research Laboratories, South Bend, IN) to react with the substrate (0.20 ιriM-1 mM) in the presence of inhibitor. Reactions were allowed to go for 30 minutes and the velocities (rate of absorbance change vs time) were measured in the time frame of 25-30 minutes. The following relationship was used to calculate Ki values: (v 0 -v s )/v s = I/(Ki (1 + S/K )) where: v 0 is the velocity of the control in the absence of inhibitor; v s is the velocity in the presence of inhibitor; I is the concentration of inhibitor; Ki is the dissociation constant of the enzyme : inhibitor complex; S is the concentration of substrate; K is the Michaelis constant. Using the methodology described above, a compound of the present invention were found to exhibit a Ki of <10 uM, thereby confirming the utility of the compounds of the present invention as effective Xa inhibitors. The antithrombotic effect of compounds of the present invention can be demonstrated in a rabbit arterio-venous (AV) shunt thrombosis model. In this model, rabbits weighing 2-3 kg anesthetized with a mixture of xylazine (10 mg/kg i.m.) and ketamine (50 mg/kg i.m.) are used. A saline-filled AV shunt device is connected between the femoral arterial and the femoral venous cannulae. The AV shunt device consists of a piece of 6-cm tygon tubing which contains a piece of silk thread. Blood will flow from the femoral artery via the AV- shunt into the femoral vein. The exposure of flowing blood to a silk thread will induce the formation of a significant thrombus. After forty minutes, the shunt is disconnected and the silk thread covered with thrombus is weighed. Test agents or vehicle will be given (i.v., i.p., s.c, or orally) prior to the opening of the AV shunt. The percentage inhibition of thrombus formation is determined for each treatment group. The ID50 values (dose which produces 50% inhibition of thrombus formation) are estimated by linear regression. The compounds of formula (I) may also be useful as inhibitors of serine proteases, notably human thrombin, plasma kallikrein and plasmin. Because of their inhibitory action, these compounds are indicated for use in the prevention or treatment of physiological reactions, blood coagulation and inflammation, catalyzed by the aforesaid class of enzymes. Specifically, the compounds have utility as drugs for the treatment of diseases arising from elevated thrombin activity such as myocardial infarction, and as reagents used as anticoagulants in the processing of blood to plasma for diagnostic and other commercial purposes . Some compounds of the present invention were shown to be direct acting inhibitors of the serine protease thrombin by their ability to inhibit the cleavage of small molecule substrates by thrombin in a purified system. In vitro inhibition constants were determined by the method described by Kettner et al . in J. Biol . Chem. 265, 18289-18297 (1990), herein incorporated by reference. In these assays, thrombin- mediated hydrolysis of the chromogenic substrate S2238 (Helena Laboratories, Beaumont, TX) was monitored spectrophotometrically. Addition of an inhibitor to the assay mixture results in decreased absorbance and is indicative of thrombin inhibition. Human thrombin (Enzyme Research Laboratories, Inc., South Bend, IN) at a concentration of 0.2 nM in 0.10 M sodium phosphate buffer, pH 7.5, 0.20 M NaCI, and 0.5% PEG 6000, was incubated with various substrate concentrations ranging from 0.20 to 0.02 mM. After 25 to 30 minutes of incubation, thrombin activity was assayed by monitoring the rate of increase in absorbance at 405 nm which arises owing to substrate hydrolysis. Inhibition constants were derived from reciprocal plots of the reaction velocity as a function of substrate concentration using the standard method of Lineweaver and Burk. Using the methodology described above, some compounds of this invention were evaluated and found to exhibit a K of less than 10 μm, thereby confirming the utility of the compounds of the present invention as effective thrombin inhibitors . The compounds of the present invention can be administered alone or in combination with one or more additional therapeutic agents. These include other anti- coagulant or coagulation inhibitory agents, anti-platelet or platelet inhibitory agents , thrombin inhibitors , or thrombolytic or fibrinolytic agents . The compounds are administered to a mammal in a therapeutically effective amount. By "therapeutically effective amount" it is meant an amount of a compound of Formula I that, when administered alone or in combination with an additional therapeutic agent to a mammal, is effective to prevent or ameliorate the thromboembolic disease condition or the progression of the disease. By "administered in combination" or "combination therapy" it is meant that the compound of Formula I and one or more additional therapeutic agents are administered concurrently to the mammal being treated. When administered in combination each component may be administered at the same time or sequentially in any order at different points in time. Thus, each component may be administered separately but sufficiently closely in time so as to provide the desired therapeutic effect. Other anticoagulant agents (or coagulation inhibitory agents) that may be used in combination with the compounds of this invention include warfarin and heparin, as well as other factor Xa inhibitors such as those described in the publications identified above under Background of the Invention. The term anti-platelet agents (or platelet inhibitory agents) , as used herein, denotes agents that inhibit platelet function such as by inhibiting the aggregation, adhesion or granular secretion of platelets. Such agents include, but are not limited to, the various known non-steroidal anti- inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, and piroxicam, including pharmaceutically acceptable salts or prodrugs thereof. Of the NSAIDS, aspirin (acetylsalicyclic acid or ASA) , and piroxicam are preferred. Other suitable anti-platelet agents include ticlopidine, including pharmaceutically acceptable salts or prodrugs thereof . Ticlopidine is also a preferred compound since it is known to be gentle on the gastro-intestinal tract in use. Still other suitable platelet inhibitory agents include lib/Ilia antagonists, thromboxane-A2-receptor antagonists and thromboxane-A2-synthetase inhibitors, as well as pharmaceutically acceptable salts or prodrugs thereof . The term thrombin inhibitors (or anti-thrombin agents) , as used herein, denotes inhibitors of the serine protease thrombin. By inhibiting thrombin, various thrombin-mediated processes, such as thrombin-mediated platelet activation (that is, for example, the aggregation of platelets, and/or the granular secretion of plasminogen activator inhibitor-1 and/or serotonin) and/or fibrin formation are disrupted. A number of thrombin inhibitors are known to one of skill in the art and these inhibitors are contemplated to be used in combination with the present compounds. Such inhibitors include, but are not limited to, boroarginine derivatives, boropeptides, heparins, hirudin and argatroban, including pharmaceutically acceptable salts and prodrugs thereof. Boroarginine derivatives and boropeptides include N-acetyl and peptide derivatives of boronic acid, such as C-terminal a-aminoboronic acid derivatives of lysine, ornithine, arginine, homoarginine and corresponding isothiouronium analogs thereof. The term hirudin, as used herein, includes suitable derivatives or analogs of hirudin, referred to herein as hirulogs, such as disulfatohirudin. Boropeptide thrombin inhibitors include compounds described in Kettner et al., U.S. Patent No. 5,187,157 and European Patent Application Publication Number 293 881 A2, the disclosures of which are hereby incorporated herein by reference. Other suitable boroarginine derivatives and boropeptide thrombin inhibitors include those disclosed in PCT Application Publication Number 92/07869 and European Patent Application Publication Number 471,651 A2, the disclosures of which are hereby incorporated herein by reference. The term thrombolytics (or fibrinolytic) agents (or thrombolytics or fibrinolytics) , as used herein, denotes agents that lyse blood clots (thrombi) . Such agents include tissue plasminogen activator, anistreplase, urokinase or streptokinase, including pharmaceutically acceptable salts or prodrugs thereof. The term anistreplase, as used herein, refers to anisoylated plasminogen streptokinase activator complex, as described, for example, in European Patent Application No. 028,489, the disclosure of which is hereby incorporated herein by reference herein. The term urokinase, as used herein, is intended to denote both dual and single chain urokinase, the latter also being referred to herein as prourokinase . Administration of the compounds of Formula I of the invention in combination with such additional therapeutic agent, may afford an efficacy advantage over the compounds and agents alone, and may do so while permitting the use of lower doses of each. A lower dosage minimizes the potential of side effects, thereby providing an increased margin of safety. The compounds of the present invention are also useful as standard or reference compounds, for example as a quality standard or control, in tests or assays involving the inhibition of factor Xa. Such compounds may be provided in a commercial kit, for example, for use in pharmaceutical research involving factor Xa. For example, a compound of the present invention could be used as a reference in an assay to compare its known activity to a compound with an unknown activity. This would ensure the experimenter that the assay was being performed properly and provide a basis for comparison, especially if the test compound was a derivative of the reference compound. When developing new assays or protocols , compounds according to the present invention could be used to test their effectiveness. The compounds of the present invention may also be used in diagnostic assays involving factor Xa. For example, the presence of factor Xa in an unknown sample could be determined by addition of chromogenic substrate S2222 to a series of solutions containing test sample and optionally one of the compounds of the present invention. If production of pNA is observed in the solutions containing test sample, but not in the presence of a compound of the present invention, then one would conclude factor Xa was present. Dosaσe and Formulation The compounds of this invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations) , pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. They may also be administered in intravenous (bolus or infusion) , intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. They can be administered alone, but generally will be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice . The dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired. A physician or veterinarian can determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the thromboembolic disorder. By way of general guidance, the daily oral dosage of each active ingredient, when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, preferably between about 0.01 to 100 mg/kg of body weight per day, and most preferably between about 1.0 to 20 mg/kg/day. Intravenously, the most preferred doses will range from about 1 to about 10 mg/kg/minute during a constant rate infusion. Compounds of this invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily. Compounds of this invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal skin patches . When administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen. The compounds are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as pharmaceutical carriers) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices . For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl callulose, magnesium stearate, dicalcium phosphate, calcium sulfate, annitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like. The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids , such as cholesterol, stearylamine, or phosphatidylcholines . Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers . Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-pheno1, polyhydroxyethylaspartamidephenol, or polyethyleneoxide- polylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans , polycyanoacylates , and crosslinked or amphipathic block copolymers of hydrogels . Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 milligram to about 100 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition. Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets . Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours . Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. In general, water, a suitable oil, saline, aqueous dextrose (glucose) , and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions . Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances . Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol . Suitable pharmaceutical carriers are described in Remington ' s Pharmaceutical Sciences . Mack Publishing Company, a standard reference text in this field. Representative useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows : Capsules A large number of unit capsules can be prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate. Soft Gelatin Capsules A mixture of active ingredient in a digestable oil such as soybean oil, cottonseed oil or olive oil may be prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules should be washed and dried. Tablets Tablets may be prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption. In ectable A parenteral composition suitable for administration by injection may be prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution should be made isotonic with sodium chloride and sterilized. Suspension An aqueous suspension can be prepared for oral administration so that each 5 mL contain 100 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, U.S. P., and 0.025 mL of vanillin. Where the compounds of this invention are combined with other anticoagulant agents, for example, a daily dosage may be about 0.1 to 100 milligrams of the compound of Formula I and about 1 to 7.5 milligrams of the second anticoagulant, per kilogram of patient body weight. For a tablet dosage form, the compounds of this invention generally may be present in an amount of about 5 to 10 milligrams per dosage unit, and the second anti-coagulant in an amount of about 1 to 5 milligrams per dosage unit . Where the compounds of Formula I are administered in combination with an anti-platelet agent, by way of general guidance, typically a daily dosage may be about 0.01 to 25 milligrams of the compound of Formula I and about 50 to 150 milligrams of the anti-platelet agent, preferably about 0.1 to 1 milligrams of the compound of Formula I and about 1 to 3 milligrams of antiplatelet agents, per kilogram of patient body weight . Where the compounds of Formula I are adminstered in combination with thrombolytic agent, typically a daily dosage may be about 0.1 to 1 milligrams of the compound of Formula I, per kilogram of patient body weight and, in the case of the thrombolytic agents, the usual dosage of the thrombolyic agent when administered alone may be reduced by about 70-80% when administered with a compound of Formula I. Where two or more of the foregoing second therapeutic agents are administered with the compound of Formula I, generally the amount of each component in a typical daily dosage and typical dosage form may be reduced relative to the usual dosage of the agent when administered alone, in view of the additive or synergistic effect of the therapeutic agents when administered in combination. Particularly when provided as a single dosage unit, the potential exists for a chemical interaction between the combined active ingredients. For this reason, when the compound of Formula I and a second therapeutic agent are combined in a single dosage unit they are formulated such that although the active ingredients are combined in a single dosage unit, the physical contact between the active ingredients is minimized (that is, reduced) . For example, one active ingredient may be enteric coated. By enteric coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines . One of the active ingredients may also be coated with a material which effects a sustained- release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients. Furthermore, the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a lowviscosity grade of hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components . The polymer coating serves to form an additional barrier to interaction with the other component. These as well as other ways of minimizing contact between the components of combination products of the present invention, whether administered in a single dosage form or administered in separate forms but at the same time by the same manner, will be readily apparent to those skilled in the art, once armed with the present disclosure. Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings . It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise that as specifically described herein.

Claims: WHAT IS CLAIMED IS ; 1. A compound of formula I : I II or a stereoisomer or pharmaceutically acceptable salt thereof, wherein; M 1 is N or CR lc ; M 2 is NR la or CR la R la , provided that only one of M 1 and M 2 is a N atom; D is selected from C (=NR 8 ) NR 7 R 9 , NHC (=NR 8 ) NR 7 R 9 , NR 8 CH(=NR 7 ), C(0)NR 7 R 8 , and CR 8 R 9 NR 7 R 8 ; E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, and piperidinyl substituted with 1 R; alternatively, D-E-G together represent pyridyl substituted with 1 R; R is selected from H, Cl, F, Br, I, (CH ) t OR 3 , C 1 - 4 alkyl, OCF 3 , CF 3 , C(0)NR 7 R 8 , and (CR 8 R 9 ) t NR 7 R 8 ; G is selected from NHCH 2 , OCH 2 , and SCH , provided that when s is 0, then G is absent; Z is selected from a Cι_ 4 alkylene, (CH 2 ) r O(CH 2 ) τ , ( CH 2 ) r R 3( CH 2 ) r, ( CH 2 ) r C (O) (CH 2 ) r , (CH 2 ) r C (0) 0 (CH 2 ) τ , (CH 2 ) r OC(0) (CH 2 ) r , (CH 2 ) r C(0)NR 3 (CH 2 ) r , (CH 2 ) r R 3 C(0) (CH 2 ) r , (CH 2 ) r OC (0) 0 (CH 2 ) r , (CH 2 ) r OC(0)NR 3 (CH 2 ) r , (CH 2 ) r NRC(0)0(CH 2 ) r , (CH 2 ) r NRC(0)NR 3 (CH 2 ) r , (CH 2 ) r S (O) p (CH 2 ) r , (CH 2 )rS0 2 NR 3 (CH 2 ) r , (CH 2 ) r NR 3 S0 2 (CH 2 ) r , and (CH 2 ) r NR 3 S0 2 NR 3 (CH 2 ) r , provided that Z does not form a N- N, N-O, N-S, NCH 2 N, NCH0, or NCH 2 S bond with group A; R la and R lb are, at each occurrence, independently selected from H, -(CH 2 )r-R 1 ', NCH2R 1 ", OCH2R 1 ", SCH2R 1 ", N ( CH 2 ) 2 ( CH 2 ) tR 1' , 0(CH 2 )2 ( CH 2 ) tR 1' ' and S ( CH 2 ) 2 ( CH 2 ) tR 1' ; R lc is selected from H, -(CH 2 ) g -R 1 ', C 1 -. 3 alkyl, C(0)R 2c , (CF 2 ) r C0 2 R 2c , C(0)NR 2 R 2a , C 3 - 6 carbocyclic residue substituted with 0-2 R 4 , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4 ; R 1 ' is selected from H, Cι_ 3 alkyl, halo, (CF 2 ) r CF 3 , OR 2 , NR 2 R 2a , C(0)R 2c , 0C(0)R 2 , (CF 2 ) r C0 2 R 2c , S(0) p R 2b , NR 2 (CH 2 ) r OR 2 , NR 2 C(0)R 2b , NR 2 C (0)NHR 2b , NR 2 C(0) 2 R 2a , OC(0)NR 2b , C(0)NR 2 R 2a , S0 2 NR 2 R 2a , NR 2 S0 2 R 2b , C 3 _ 6 carbocyclic residue substituted with 0-2 R 4 , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R 4 ; R 1 " is selected from H, C(0)R 2b , C(0)NR 2 R 2a , S(0)R 2b , S(0) 2 R 2b , and S0 2 NR 2 R 2a ; R 2 , at each occurrence, is selected from H, CF 3 , Cχ- 6 alkyl, benzyl, C 3 -. 6 carbocyclic residue substituted with 0-2 R 4b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4b ; R a , at each occurrence, is selected from H, CF 3 , Cχ- 6 alkyl, benzyl, C 3 - 6 carbocyclic residue substituted with 0-2 R b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R 4b ; R 2b , at each occurrence, is selected from CF 3 , Cι_ 4 alkoxy, Cι_ 6 alkyl, benzyl, C 3 _ 6 carbocyclic residue substituted with 0-2 R 4b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R 4b ; R 2c , at each occurrence, is selected from CF 3 , OH, C 1 -. 4 alkoxy, C 1 - 6 alkyl, benzyl, C 3 - 6 carbocyclic residue substituted with 0-2 R 4b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R b ; alternatively, R 2 and R 2a combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R b which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S; R 3 , at each occurrence, is selected from H, C 1 - 4 alkyl, and phenyl; R 3a , at each occurrence, is selected from H, Cι_ 4 alkyl, and phenyl ; A is selected from: C 3 -. 10 carbocyclic residue substituted with 0-2 R 4 , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4 ; B is selected from: X-Y, NR 2 R 2 , C(=NR 2 )NR 2 R 2a , NR 2 C (=NR 2 ) NR 2 R 2a , C 3 -. 10 carbocyclic residue substituted with 0-2 R a , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4a ; X is selected from C 3. - 4 alkylene, -CR 2 (CR 2 R 2b ) (CH 2 ) t~ ■ -C(O)- -C(=NR)-, -CR 2 (NR 1 "R 2 )-, -CR 2 (OR 2 )-, -CR 2 (SR 2 )-, -C(0)CR 2 R 2a -, -CR 2 R a C(0), -S(0) p -, -S (0) p CR 2 R 2a -, -CR 2 R 2a S(0) p -, -S(0) 2 NR 2 -, -NR 2 S(0) 2 -, -NR 2 S (0) 2 CR 2 R 2a -, -CR 2 R 2a S(0) 2 NR 2 -, -NR 2 S(0) 2 NR 2 -, -C(0)NR 2 -, -NR 2 C(0)-, -C(0)NR 2 CR 2 R 2a -, -NR 2 C(0)CR 2 R 2a -, -CR 2 R 2a C (O)NR 2 -, -CR 2 R 2a NR 2 C(0)-, -NR 2 C(0)0-, -OC(0)NR 2 -, -NR 2 C (O)NR 2 -, -NR 2 -, -NR 2 CR 2 R 2a -, -CR 2 R 2a NR 2 -, 0, -CR 2 R 2a O-, and -OCR 2 R 2a - ; Y is selected from: (CH 2 ) r NR 2 R 2a , provided that X-Y do not form a N-N, 0-N, or S-N bond, C 3 -. 10 carbocyclic residue substituted with 0-2 R 4a , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4a ; R 4 , at each occurrence, is selected from =0, (CH 2 ) r OR 2 / halo, Cι_ alkyl, -CN, N0 2 , (CH 2 ) r NR 2 R 2a , (CH 2 ) r C (0) R 2b , NR 2 C(0)R 2b , C(0)NR 2 R 2a , NR 2 C (0)NR 2 R 2a , CH (=NR 2 ) NR 2 R 2a , NHC(=NR 2 )NR 2 R 2a , S0 2 NR 2 R 2a , NR 2 S0 2 NR 2 R 2a , NR 2 S0 2 -Cι_4 alkyl, NR 2 S0 2 R 5 , S(0) p R 5 , (CF 2 ) r CF 3 , NCH 2 R 1 ", OCH2R 1 ", SCH 2 R 1 ", N(CH 2 )2(CH 2 ) t R 1 ', 0(CH 2 ) 2 (CH 2 ) t R 1 ', and S(CH 2 ) 2 (CH 2 ) t R 1 ', alternatively, one R 4 is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S; R , at each occurrence, is selected from =0, (CH 2 ) r OR 2 ' halo, Cι_ 4 alkyl, -CN, N0 2 , (CH 2 ) r NR 2 R 2a , (CH 2 ) r C (0) R 2b , NR 2 C(0)R 2b , C(0)NR 2 R 2a , NR 2 C (0)NR 2 R 2a , CH (=NR 2 ) NR 2 R 2a , NHC(=NR 2 )NR 2 R 2a , S0 2 NR 2 R 2a , NR 2 S0 2 NR 2 R 2a , NR 2 S0 2 -Cι_ alkyl, NR 2 S0 2 R 5 , S(0) p R 5 , and (CF 2 ) r CF 3 ; alternatively, one R a is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-1 R 5 ; R 4 , at each occurrence, is selected from =0, (CH 2 ) r OR 3 , halo, Ci-4 alkyl, -CN, N0 2 , (CH 2 ) r NR 3 R 3a , (CH 2 ) r C (0) R 3 , NR 3 C(0)R 3a , C(0)NR 3 R 3a , NR 3 C (0)NR 3 R 3a , CH(=NR 3 )NR 3 R 3 , NH 3 C(=NR 3 )NR 3 R 3a , S0 2 NR 3 R 3 , NR 3 S0 2 NR 3 R 3a , NR 3 Sθ2-Cι_4 alkyl, NR 3 S0 2 CF 3 , NR 3 S0 2 -phenyl , S(0) P CF 3 , S(0) p -Ci- alkyl, S (0) p -phenyl, and (CF 2 )rCF 3 ; R 5 , at each occurrence, is selected from CF3, Cι_ 6 alkyl, phenyl substituted with 0-2 R 6 , and benzyl substituted with 0-2 R 6 ; R 6 , at each occurrence, is selected from H, OH, (CH2) r OR 2 , halo, C1-4 alkyl, CN, N0 2 , (CH 2 ) r NR 2 R a , (CH 2 ) r C (0)R 2b , NR 2 C(0)R 2b , NR 2 C(0)NR 2 R 2a , CH(=NH)NH 2 , NHC(=NH)NH 2 , S0 2 NR 2 R 2a , NR 2 Sθ2NR 2 R 2 , and NR 2 S0 2 Ci-4 alkyl; R 7 , at each occurrence, is selected from H, OH, Cι_ 6 alkyl, Cι_6 alkylcarbonyl , C±-β alkoxy, C1-.4 alkoxycarbonyl, (CH 2 ) n -phenyl, C δ -io aryloxy, Cβ-io aryloxycarbonyl , C δ -io arylmethylcarbonyl , C1-4 alkylcarbonyloxy C 1 -4 alkoxycarbonyl, Cβ-io arylcarbonyloxy Cι_4 alkoxycarbonyl, C1- 6 alkylaminocarbonyl , phenylaminocarbonyl , and phenyl C1-4 alkoxycarbonyl; R 8 , at each occurrence, is selected from H, Cι_ 6 alkyl and (CH 2 ) n -phenyl; alternatively, R 7 and R 8 combine to form a 5 or 6 membered saturated, ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S; R 9 , at each occurrence, is selected from H, Ci-e alkyl and (CH 2 ) n -phenyl; n, at each occurrence, is selected from 0, 1, 2, and 3; m, at each occurrence, is selected from 0, 1, and 2; p, at each occurrence, is selected from 0, 1, and 2; q, at each occurrence is selected from 1 and 2; r, at each occurrence, is selected from 0, 1, 2, and 3; s, at each occurrence, is selected from 0, 1, and 2; and, t, at each occurrence, is selected from 0 and 1. 2. A compound according to Claim 1 , wherein the compound is of formula la or lb: wherein; Z is selected from a CH 2 0, OCH 2 , CH 2 NH, NHCH 2 , C(O), CH 2 C(0), C(0)CH 2 , NHC(O), C(0)NH, CH 2 S(0) 2 , S(0) 2 (CH 2 ), S0 2 NH, and NHSO 2 , provided that Z does not form a N-N, N-O, NCH 2 N, or NCH 2 O bond with group A; A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl, 1, 2 , 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2,3 -thiadiazolyl , 1,2, 4-thiadiazolyl , 1, 2 , 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2 , 3 -triazolyl, 1,2, 4-triazolyl, 1, 2, 5-triazolyl, 1, 3 , 4-triazolyl, benzofuranyl , benzothiofuranyl , indolyl, benzimidazolyl, benzoxazolyl , benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl , and isoindazolyl ; B is selected from: Y, X-Y, NR 2 R 2a , C (=NR 2 )NR 2 R 2a , and NR 2 C(=NR 2 )NR 2 R 2a ; X is selected from C1-4 alkylene, -C(O)-, -C(=NR)-, -CR 2 (NR 2 R 2a )-, -C(0)CR 2 R 2 -, -CR 2 R 2a C(0), -C(0)NR 2 -, -NR 2 C(0)-, -C(0)NR 2 CR 2 R 2a -, -NR 2 C (0) CR 2 R 2a -, -CR 2 R 2a C(0)NR 2 -, -CR 2 R 2a NR 2 C (O) - , -NR 2 C (0) NR 2 - , -NR 2 -, -NR 2 CR 2 R 2a -, -CR 2 R 2a NR 2 -, 0, -CR 2 R 2a O- , and -OCR 2 R 2a -; Y is NR 2 R 2a , provided that X-Y do not form a N-N or 0-N bond; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R a ; cylcopropyl, cyclopentyl, cyclohexyl, phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl , thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2, 3-oxadiazolyl, 1, 2 , 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2 , 3-thiadiazolyl, 1, 2, 4-thiadiazolyl, 1,2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2 , 3-triazolyl, 1,2, 4-triazolyl, 1, 2, 5-triazolyl, 1, 3 , 4-triazolyl, benzofuranyl , benzothiofuranyl , indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl; alternatively, Y is selected from the following bicyclic heteroaryl ring systems : K is selected from 0, S, NH, and N. A compound according to Claim 2, wherein; Z is selected from a C(0), CH 2 C(0), C(0)CH , NHC(O), C(0)NH, C(0)N(CH 3 ), CH 2 S(0) 2 , S(0) 2 (CH 2 ), S0 2 NH, and NHS0 2 , provided that Z does not form a N-N or NCH 2 N bond with group A. 4. A compound according to Claim 3, wherein; E is phenyl substituted with R or 2-pyridyl substituted with R; D is selected from C(0)NH 2 , C(=NH)NH 2 , CHNH 2 , CH 2 NHCH 3 , CH(CH 3 )NH 2 , and C(CH 3 ) 2 NH 2 ; and, R is selected from H, OCH 3 , Cl, and F. 5. A compound according to Claim 4, wherein; D-E is selected from 3-amidinophenyl, 3-aminomethylphenyl, 3- aminocarbonylphenyl , 3- (methylaminomethyl) phenyl, 3- ( 1- aminoethyl) phenyl , 3- (2-amino-2-propyl) phenyl , 4-chloro- 3-amidinophenyl, 4-chloro-3-aminomethylphenyl, 4-chloro- 3-(methylaminomethyl) phenyl, 4-fluoro-3-amidinophenyl, 4- fluoro-3-aminomethylphenyl , 4-fluoro-3- (methylaminomethyl) phenyl, 6-amidinopyrid-2-yl, 6- aminomethylpyrid-2-yl, 6-aminocarbonylpyrid-2-yl, 6- (methylaminomethyl) pyrid-2-yl , 6- ( 1-aminoethyl) pyrid-2- yl, and 6- (2-amino-2-propyl)pyrid-2-yl. 6. A compound according to Claim 3, wherein; Z is C(0)CH and CONH, provided that Z does not form a N-N bond with group A; A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R 4 ; and, B is selected from X-Y, phenyl, pyrrolidino, morpholino, 1, 2, 3-triazolyl, and imidazolyl, and is substituted with 0-1 R 4a ; R 4 , at each occurrence, is selected from OH, (CH 2 ) r OR 2 halo, Cι-4 alkyl, (CH 2 ) r NR 2 R 2a , and (CF 2 ) r CF 3 ; R 4a is selected from C1-4 alkyl, CF 3 , S(0) p R 5 , S0 2 NR 2 R 2a , and l-CF3-tetrazol-2-yl; R 5 , at each occurrence, is selected from CF3, Cι_6 alkyl, phenyl, and benzyl; X is CH 2 or C(O); and, Y is selected from pyrrolidino and morpholino. 7. A compound according to Claim 6, wherein; A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl, 2-aminophenyl, and 2- methoxyphenyl ; and, B is selected from the group: 2-CF3 -phenyl, 2- (aminosulfonyl ) phenyl , 2- (methylaminosulfonyl ) phenyl , 2- (dimethylaminosulfonyl) phenyl, 1-pyrrolidinocarbonyl, 2- (methylsulfonyl) phenyl , 4-morpholino, 2- (1 ' -CF3~tetrazol- 2-yl)phenyl, 4-morpholinocarbonyl, 2-methyl-l-imidazolyl, 5-methyl-l-imidazolyl, 2-methylsulfonyl-l-imidazolyl and, 5-methyl-l, 2, 3 -triazolyl . 8. A compound according to Claim 3, wherein; E is phenyl substituted with R or 2-pyridyl substituted with R; D is selected from C(0)NH 2 , C(=NH)NH 2 , CH 2 NH 2 , CH 2 NHCH 3 , CH(CH 3 )NH 2 , and C(CH 3 )2NH 2 ; and, R is selected from H, OCH 3 , Cl, and F; Z is C(0)CH and CONH, provided that Z does not form a N-N bond with group A; A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R 4 ; and, B is selected from X-Y, phenyl, pyrrolidino, morpholino, 1, 2, 3-triazolyl, and imidazolyl, and is substituted with 0-1 R a ; R 4 , at each occurrence, is selected from OH, (CH 2 ) r OR 2 , halo, C1-4 alkyl, (CH 2 ) r NR 2 R 2a , and (CF 2 )rCF 3 ; R 4a is selected from C1-4 alkyl, CF3, S(0) p R 5 , S0 2 NR 2 R 2a , and I-CF3-tetrazol-2-yl; R 5 , at each occurrence, is selected from CF3, Cχ_ 6 alkyl, phenyl, and benzyl; X is CH 2 or C(O); and, Y is selected from pyrrolidino and morpholino. 9. A compound according to Claim 8 wherein; D-E is selected from 3-amidinophenyl, 3-aminomethylphenyl, 3- aminocarbonylphenyl , 3- (methylaminomethyl)phenyl, 3- (1- aminoethyl) phenyl, 3- (2-amino-2-propyl) phenyl , 4-chloro- 3-amidinophenyl, 4-chloro-3-aminomethylphenyl, 4-chloro- 3- (methylaminomethyl) phenyl , 4-fluoro-3-amidinophenyl , 4- fluoro-3-aminomethylphenyl, 4-fluoro-3- (methylaminomethyl) phenyl, 6-amidinopyrid-2-yl, 6- aminomethylpyrid-2-yl, 6-aminocarbonylpyrid-2-yl, 6- (methylaminomethyl)pyrid-2-yl, 6- (l-aminoethyl)pyrid-2- yl, 6- (2-amino-2-propyl)pyrid-2-yl; A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl , 2-aminophenyl, and 2- methoxyphenyl ; and, B is selected from the group: 2-CF3-phenyl, 2- (aminosulfonyl) phenyl , 2- (methylaminosulfonyl) phenyl , 2- (dimethylaminosulfonyl)phenyl, 1-pyrrolidinocarbonyl, 2- (methylsulfonyl)phenyl, 4-morpholino, 2- (1' -CF3~tetrazol- 2-yl)phenyl, 4-morpholinocarbonyl, 2-methyl-l-imidazolyl, 5-methyl-l-imidazolyl, 2-methylsulfonyl-l-imidazolyl and, 5-methyl-l, 2, 3-triazolyl . 10. A compound according to Claim 9 , wherein the compound is of formula la. 11. A compound according to Claim 9 , wherein the compound is of formula lb. 12. A compound according to Claim 3, wherein; D is selected from C (=NR 8 ) NR 7 R 9 , C(0)NR 7 R 8 , NR 7 R 8 , and CH 2 NR 7 R 8 ; E is phenyl substituted with R or pyridyl substituted with R; R is selected from H, Cl, F, OR 3 , CH 3 , CH 2 CH 3 , OCF 3 , and CF 3 ; Z is selected from C(O), CHC(0), C(0)CH 2 , NHC(O), and C(0)NH, provided that Z does not form a N-N bond with group A; R la and R lb are, at each occurrence, independently selected from H, -(CH^r-R 1 ', NCH 2 R 1 ", OCH 2 R 1 ", SO^R 1 ", N(CH 2 ) 2 (CH 2 ) t R 1 ', 0(CH 2 )2(CH 2 ) t R 1 ', and S (CH 2 ) 2 (CH 2 ) t R l' ; R lc i s selected from H, -(CH^ g -R 1 ', C 1 - 3 alkyl, C(0)R 2c , (CF 2 ) r C0 2 R 2c , and C(0)NR 2 R 2a ; R 1 ', at each occurrence, is selected from H, C 1 -. 3 alkyl, halo, (CF ) r CF 3 , OR 2 , NR 2 R 2 , C(0)R 2c , (CF 2 ) r C0R 2c , S(0) p R 2b , NR 2 (CH 2 ) r OR 2 , NR 2 C(0)R 2b , NR 2 C(0) 2 R 2b , C(0)NR 2 R 2a , S0 2 NR 2 R 2 , and NR 2 S0R 2b ; A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, and imidazolyl; B is selected from: Y, X-Y, NR 2 R 2a , C (=NR 2 )NR 2 R 2a , and NR 2 C (=NR 2 ) NR 2 R 2a ; X is selected from CH 2 , -CR 2 (CR 2 R 2b ) (CH 2 ) t -, -C(O)-, -C(=NR)-, -CH(NR 2 R 2a )-, -C(0)NR 2 -, -NR 2 C(0)-, -NR 2 C (O)NR 2 - , -NR 2 -, and 0; Y is NR 2 R 2a , provided that X-Y do not form a N-N or 0-N bond; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4a ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3-oxadiazolyl, 1,2, 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1,2, 4-thiadiazolyl, 1,2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2, 3-triazolyl, 1,2, 4-triazolyl, 1, 2, 5-triazolyl, and 1,3, 4-triazolyl; R 4 , at each occurrence, is selected from =0, OH, Cl, F, C 1 - 4 alkyl, (CH 2 ) r NR 2 R 2a , (CH 2 ) r C (O) R 2b , NR 2 C(0)R 2b , C(0)NR 2 R 2a , CH(=NH)NH 2 , NHC(=NH)NH , S0 2 NR 2 R 2a , NR 2 S0 2 -Cι_ alkyl, NR 2 S0 2 R 5 , S(0) p R 5 , and (CF 2 ) r CF 3 ; R 4a , at each occurrence, is selected from =0, OH, Cl, F, C 1 -. 4 alkyl, (CH 2 ) r NR 2 R 2a , (CH 2 ) r C (0)R 2b , NR 2 C(0)R 2b , C(0)NRR 2a , CH(=NH)NH 2 , NHC(=NH)NH 2 , S0 2 NR 2 R 2a , NR 2 S0 2 -Ci- 4 alkyl, NR 2 S0 2 R 5 , S(0) P R 5 , (CF 2 ) r CF 3 , and l-CF 3 -tetrazol-2-yl; R 5 , at each occurrence, is selected from CF 3 , Cι_ 6 alkyl, phenyl substituted with 0-2 R 6 , and benzyl substituted with 0-2 R 6 ; R 6 , at each occurrence, is selected from H, =0, OH, OR 2 , Cl, F, CH 3 , CN, N0 2 , (CH 2 ) r R 2 R 2a , (CH 2 ) r C (0)R 2b , NR 2 C(0)R 2b , CH(=NH)NH 2 , NHC(=NH)NH 2 , and S0 2 NR 2 R 2a ; R 7 , at each occurrence, is selected from H, OH, Cχ_ 6 alkyl, Cι_β alkylcarbonyl, Cχ_ 6 alkoxy, C 1 -. 4 alkoxycarbonyl, benzyl, Cβ-io aryloxy, Cβ-io aryloxycarbony1 , Cβ-io arylmethylcarbony1, C 1 -. 4 alkylcarbonyloxy C 1 -. 4 alkoxycarbonyl, Cg-io arylcarbonyloxy C 1 - 4 alkoxycarbonyl, Cι_ 6 alkylaminocarbonyl , phenylaminocarbonyl , and phenyl Cι_ 4 alkoxycarbonyl ; R 8 , at each occurrence, is selected from H, C 1 - 6 alkyl and benzyl; and alternatively, R 7 and R 8 combine to form a morpholino group; and, R 9 , at each occurrence, is selected from H, Cι_e alkyl and benzyl . 13. A compound according to Claim 12, wherein; E is phenyl substituted with R or 2-pyridyl substituted with R; R is selected from H, Cl, F, OCH 3 , CH 3 , OCF 3 , and CF 3 ; Z is selected from a C(0)CH 2 and C(0)NH, provided that Z does not form a N-N bond with group A; R la , at each occurrence, is selected from H, CH 3 , CHCH 3 , Cl, F, CF 3 , OCH 3 , NR 2 R 2a , S(0) p R 2b , CH 2 S(0) p R 2b , CH 2 NR 2 S(0) p R 2b , C(0)R 2c , CH 2 C(0)R 2c , C(0)NR 2 R 2a , and S0 2 NR 2 R 2a ; Ri b i s selected from H, CH 3 , CH 2 CH 3 , Cl, F, CF 3 , OCH 3 , NR 2 R 2a , S(0) p R 2b , CH 2 S(0) p R 2b , CH 2 NR 2 S (0) p R 2b , C(0)R 2c , CH 2 C(0)R 2c , C(0)NR 2 R 2a , and S0 2 NR 2 R 2 ; RI C i s selected from H, CH 3 , CHCH 3 , CF 3 , CH 2 S(0) p R 2b , CH 2 NR 2 S(0) p R 2b , C(0)R 2c , CH 2 C(0)R 2 , and C(0)NR 2 R 2a ; A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ; phenyl, pyridyl, pyrimidyl, furanyl, thiophenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, and imidazolyl; B is selected from: Y and X-Y; X is selected from CH 2 , -CR 2 (CR 2 R 2b ) -, -C(O)-, -C(=NR)-, -CH(NR 2 R 2a )-, -C(0)NR 2 -, -NR 2 C(0)-, -NR 2 C (O)NR 2 - , -NR 2 -, and 0; Y is NRR 2a , provided that X-Y do not form a N-N or 0-N bond; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4a ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3 -oxadiazolyl, 1,2 , 4-oxadiazolyl, 1, 2, 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1,2, 4-thiadiazolyl, 1,2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2 , 3-triazolyl, 1,2, 4-triazolyl, 1, 2, 5-triazolyl, and 1, 3 , 4-triazolyl; R 2 , at each occurrence, is selected from H, CF 3 , CH3, benzyl, and phenyl; R 2a , at each occurrence, is selected from H, CF3, CH3, benzyl, and phenyl; R b , at each occurrence, is selected from CF3, OCH 3 , CH3, benzyl, and phenyl; R 2c , at each occurrence, is selected from CF 3 , OH, OCH 3 , CH 3 , benzyl, and phenyl; alternatively, R 2 and R 2a combine to form a 5 or 6 membered saturated, partially unsaturated, or unsaturated ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, O, and S; R 3 , at each occurrence, is selected from H, CH 3 , CH 2 CH 3 , and phenyl ; R 3a , at each occurrence, is selected from H, CH 3 , CH 2 CH 3 , and phenyl ; R 4 , at each occurrence , is selected from OH, Cl , F , CH3 , CH2CH 3 , NR 2 R 2a , CH 2 NR 2 R 2a , C (0 ) R 2b , NR 2 C (0) R 2b , C (0) NR 2 R 2a , and CF 3 ; R a , at each occurrence, is selected from OH, Cl, F, CH 3 , CH 2 CH 3 , NR 2 R 2a , CH 2 NR 2 R 2a , C(0)R 2b , C(0)NR 2 R 2a , S0 2 NR 2 R 2a , S(0) p R 5 , CF 3 , and l-CF 3 -tetrazol-2-yl; R 5 , at each occurrence, is selected from CF 3 , Cι_ 6 alkyl, phenyl substituted with 0-2 R 6 , and benzyl substituted with 1 R 6 ; R 6 , at each occurrence, is selected from H, OH, OCH 3 , Cl, F, CH 3 , CN, N0 2 , NR 2 R 2a , CH 2 NR 2 R 2a , and S0 2 NR 2 R 2a ; R 7 , at each occurrence, is selected from H, OH, Cι_ 3 alkyl, Cι_ 3 alkylcarbonyl, C 1 -. 3 alkoxy, C 1 -. 4 alkoxycarbonyl, benzyl, phenoxy, phenoxycarbonyl , benzylcarbonyl, C 1 -. 4 alkylcarbonyloxy C 1 -. 4 alkoxycarbonyl, phenylcarbonyloxy Cχ_ 4 alkoxycarbonyl, C 1 - 6 alkylaminocarbonyl, phenylaminocarbonyl, and phenyl Cχ_ 4 alkoxycarbonyl; R 8 , at each occurrence, is selected from H, CH 3 , and benzyl; and, alternatively, R 7 and R 8 combine to form a morpholino group; R 9 , at each occurrence, is selected from H, CH 3 , and benzyl. 14. A compound according to Claim 13, wherein; R la , at each occurrence, is selected from H, CH 3 , CHCH 3 , Cl, F, CF 3 , OCH 3/ NR 2 R 2a , S(0) p R 2b , C(0)NR 2 R 2 , CH 2 S(0) p R 2b , CH 2 NR 2 S(0) p R 2b , C(0)R 2c , CH 2 C(0)R 2c , and S0 2 NR 2 R 2a ; R lb is selected from H, CH 3 , CH 2 CH 3 , Cl, F, CF 3 , OCH 3 , NR 2 R 2a , S(0) p R 2b , C(0)NR 2 R 2a , CH 2 S(0) p R 2b , CH 2 NR 2 S (0) p R 2b , C(0)R 2b , CHC(0)R 2b , and S0 2 NR 2 R 2a ; R lc i s selected from H, CH 3 , CH 2 CH 3 , CF 3 , C(0)NR 2 R 2a , CHS(0) p R 2b , CH 2 NR 2 S(0) p R 2b , C(0)R 2b , and CH 2 C(0)R 2b ; A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ; phenyl, pyridyl, and pyrimidyl; B is selected from: Y and X-Y; X is selected from -C(O)- and O; Y is NR 2 R 2a , provided that X-Y do not form a 0-N bond; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R ; phenyl, piperazinyl, pyridyl, pyrimidyl, morpholinyl, pyrrolidinyl, imidazolyl, and 1,2,3- triazolyl ; R 2 , at each occurrence, is selected from H, CF 3 , CH3, benzyl, and phenyl; R 2a , at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl; R 2b , at each occurrence, is selected from CF 3 , OCH 3 , CH 3 , benzyl, and phenyl; R 2c , at each occurrence, is selected from CF 3 , OH, OCH 3 , CH 3 , benzyl, and phenyl; alternatively, R 2 and R 2 combine to form a ring system selected from pyrrolidinyl, piperazinyl and morpholino; R 4 , at each occurrence, is selected from Cl, F, CH 3 , NR 2 R 2a , and CF 3 ; R a , at each occurrence, is selected from Cl, F, CH 3 , S0 2 NR 2 R 2a , S(0) P R 5 , and CF 3 ; and, R 5 , at each occurrence, is selected from CF 3 and CH 3 . 15. A compound according to Claim 1, wherein the compound is selected from the group: 1- (3-amidinophenyl) -5- [ [ (2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4- yl) -aminocarbonyl] -3-trifluoromethyl-pyrazoline; and, 1- (3-aminomethylphenyl) -5- [ [ (2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) -aminocarbonyl] -3-trifluoromethyl-pyrazoline; and pharmaceutically acceptable salts thereof. 16. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to one of Claims 1-15 or a pharmaceutically acceptable salt thereof. 17. A method for treating or preventing a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to one of Claims 1-15 or a pharmaceutically acceptable salt thereof.

Inventors: PINTO DONALD J P, PINTO, DONALD, J., P.
Applicants: DU PONT PHARM CO, DU PONT PHARMACEUTICALS COMPANY
Application year: 1999
Main classification: C07D249
IPC codes: A61K31, A61P7, A61P43, C07D231, C07D249, C07D401, C07D403